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Type 1 diabetes affects one in every 400-600 children and adolescents in the US. 
Standard therapy with exogenous insulin is burdensome, associated with a significant risk 
of dangerous hypoglycemia, and only partially efficacious in preventing the long term 
complications of diabetes. Pancreatic islet transplantation has emerged as a promising 
therapy for type 1 diabetes. However, this cell-based therapy is significantly limited by 
inadequate islet supply (more than one donor pancreas is needed per recipient), instant 
blood-mediated inflammatory reaction, and loss of islet viability/function during isolation 
and following implantation. In particular, inadequate revascularization of transplanted 
islets results in reduced islet viability, function, and engraftment. Delivery of pro-
vascularization factors has been shown to improve vascularization and islet function, but 
these strategies are hindered by insufficient and/or complex release pharmacokinetics and 
inadequate delivery matrices as well as technical and safety considerations. We 
hypothesized that controlled presentation of angiogenic cues within a bioartificial matrix 
could enhance the vascularization, viability, and function of transplanted islets. The 
primary objective of this dissertation was to enhance allogenic islet engraftment, survival 
and function by utilizing synthetic hydrogels as engineered delivery matrices. 
Polyethylene glycol (PEG)-maleimide hydrogels presenting cell adhesive motifs and 
vascular endothelial growth factor (VEGF) were designed to support islet activities and 
promote vascularization in vivo. We analyzed the material properties and 
cytocompatibility of these engineered materials, islet engraftment in an allo-
transplantation model, and glycemic control in diabetic subjects. The rationale for this 
project is to establish novel biomaterial strategies for islet delivery that support islet 








 Pancreatic islet transplantation has emerged as a promising strategy for the 
treatment of Type 1 diabetes. However, cell-based transplantation therapies are limited 
by inadequate blood supply and loss of viability/function following implantation resulting 
in incomplete or transient regeneration. Additionally, the scarce availability of islet 
donors significantly limits this potential therapy where two or more donors are required 
for each recipient due to low levels of engraftment and viability.  
 The objective of this project is to enhance allogenic islet engraftment, survival, 
and function through the use of engineered synthetic hydrogels that present cell adhesive 
cues and angiogenic factors. My hypothesis is that pancreatic islets encapsulated in 
vascular-inductive matrices will exhibit improved viability and endocrine function 
compared to non-encapsulated pancreatic islets or islets transplanted in non-vascularizing 
matrices. Additionally, we hypothesize that improved islet vascularization and viability 
will translate to improved glycemic control in diabetic animal recipients. The objective 
will be accomplished through completion of the following aims: 
 
1: Engineering of bio-functionalized PEG-maleimide hydrogel to support pancreatic 
islet encapsulation 
 We have succeeded in producing protease-degradable PEG hydrogels presenting 
cell-adhesive domains and angiogenic growth factors using a novel crosslinking moiety. 
We show that these maleimide cross-linked gels exhibit improved crosslinking and cyto-
compatibility characteristics compared to several types of previously published PEG 
hydrogels. These materials promote encapsulated islet survival and endocrine function in 
vitro as measured by insulin production, Live/Dead staining, and metabolic 
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measurements. In addition, encapsulated islets respond to gels with tethered growth 
factor and adhesive ligands by extending endothelial cells sprouts into the surrounding 
matrix. 
 
2: In vivo vascularization potential of engineered PEG-maleimide hydrogel and islet 
grafting in healthy rats 
 We hypothesized that engineered constructs exhibiting protease degradable sites, 
cell adhesion ligands, and vascular-inductive growth factors will become highly 
vascularized. Our objective was to connect encapsulated pancreatic islets with invading 
vasculature to enhance islet transplant engraftment and function. In our assessment of 
islet engraftment and vascularization through histology/immunohistochemistry as well as 
microCT imaging and quantitative analysis of implant vasculature we observed that 
degradable hydrogels incorporating bioactive ligands and growth factors resulted in 
improved islet survival and re-vascularization of the intra-islet capillary bed over non-
vascularizing hydrogels or islets transplanted in control alginate gels. 
 
3: Transplantation of hydrogel-encapsulated pancreatic islets in a rat model of type-
1 diabetes 
 We hypothesized that enhanced islet vascularization and survival from engineered 
hydrogels would translate into improved glycemic control and a possible return to 
normoglycemia in STZ-induced diabetic rats over islets transplanted alone or through the 
hepatic portal system. We monitored diabetic rats receiving islet transplants for weight 
gain/loss, blood glucose, circulating insulin levels, and response to a glucose bolus 
challenge in multiple trials. We observed moderately significant changes in weight gain, 




 The research completed for this thesis is highly innovative because it developed a 
fully synthetic bioactive material that can be precisely tailored for controlled, on-demand 
release of angiogenic factors. This approach is entirely different from other hydrogel 
encapsulation or cell-delivery vehicles that attempt to achieve immuno-isolation or rely 
on poorly controlled growth factor release. The novel innovation strategy of the 
completed work lies in both the on-demand availability of the growth factor that is only 
released as the matrix degrades, the tailorability of the individual bioactive components, 
and a novel crosslinking reaction that occurs rapidly enough for in vivo delivery while 





Figure 1.1 Engineered matrix for re-vascularization of transplanted islets concept 
illustrating blood vessels growing into a delivery matrix, attracted by growth factors, and 








Vascularization in regenerative medicine 
 
Introduction 
The ability to exploit angiogenesis and vascularization as a therapeutic strategy 
will be of enormous benefit to a wide range of medical and tissue engineering 
applications.  Angiogenic growth factor and cell-based therapies have thus far failed to 
produce a robust healing response in clinical trials for a variety of ischemic diseases, 
while engineered tissue substitutes are size-limited by a lack of vascularization.  Recent 
advances focus on better regulation of growth factor delivery and attempts to better 
mimic natural processes by delivering combinations of multiple growth factors, cells, and 
bioactive materials in the right spatial and temporal setting.  A number of disease states 
are related to reduced vascular perfusion and could be treated with pro-vascularization 
strategies.  Peripheral vascular disease, ischemic heart disease, wound healing, and cell 
and tissue transplantation are just a few examples that would greatly benefit from pro-
angiogenic therapies.  Aging patients also suffer from slower healing responses, 
especially after surgery and during fracture repair [1].  Pro-angiogenic therapy is likely to 
improve the healing response of elderly patients in many situations.  While research in 
the field of tissue engineering has been active for several decades, there are still relatively 
                                                 
∗ adapted from: 
Phelps, E.A., and Garcia, A.J. Update on therapeutic vascularization strategies, Regen. 
Med. 2009 4(1):65-80 
Phelps, E.A., and Garcia, A.J. Engineering more than a cell: vascularization strategies in 
tissue engineering. Curr. Opin. Biotechnol. 2010 21(5):705-9 
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few effective clinical implementations of tissue engineering technology.  Clinical use of 
engineered tissues and tissue substitutes is largely limited to avascular or thin tissue types 
such as cartilage, bladder, and skin.  Great progress has been attained in the development 
of a variety of engineered tissue types that function on a small scale in vitro, but these 
ultimately suffer from a lack of vascular perfusion when scaled up to a size relevant for 
implantation and disease treatment.  Researchers have been working hard to overcome 
this limitation and are developing a number of innovative strategies for vascularizing 
engineered tissues. 
Human trials in therapeutic vascularization have had limited success to date 
despite promising results in animals with experimentally induced ischemia [2].  Most 
therapeutic clinical trials have focused on delivery of a single gene or growth factor, 
commonly various isoforms of vascular endothelial growth factor (VEGF) or fibroblast 
growth factor (FGF), as discussed in detail in several review articles [3-7].  Cell 
transplantation therapy has also been tested clinically to treat myocardial and peripheral 
ischemia with promising results, reviewed in [5, 7-10].  The FDA has designated the 
primary endpoint for approval of a post-myocardial infarction angiogenic agent as an 
improvement in exercise performance.  Several clinical trials have shown angiogenic 
therapy to alleviate certain secondary symptoms such as chest pain, but failed to show a 
significant difference in exercise performance.  Part of the reason for this lack of 
enhanced performance is a strong placebo effect in control groups and difficulty in 
selecting an ideal patient cohort [11].  However, the results of Phase I and II trials also 
indicate that pro-angiogenic gene and protein therapy is generally safe and feasible.  
Critics have expressed a number of concerns for pro-angiogenic therapy including the 
potential for triggering growth of latent tumors, increasing the risk for retinopathy, and 
promotion or destabilization of atherosclerotic plaques.  In studies to date, none of these 
potential issues has been noted to be above baseline for the study population.  Some less 
serious side effects associated with administration of VEGF and FGF-2 include 
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hypotension, vascular leakage, transient tissue edema, and renal insufficiency.  Clinicians 
continue to express optimism for the future of pro-angiogenic therapy and a number of 
promising new strategies are currently under investigation.  At present, a large focus of 
clinical and preclinical studies is focused on identifying the ideal angiogenic agent (or 
combination therapy), delivery strategy, and dosing regimen. 
 
Review of Angiogenesis Mechanisms 
The formation of the vascular network is a finely tuned and complex process 
controlled by the signaling balance between integrins, angiopoietins, chemokines, 
junctional molecules, oxygen sensors, endogenous inhibitors, and many others [12].  
Several excellent review articles give a detailed description of the mechanisms of 
angiogenesis [13-15].  There are three main mechanisms of new blood vessel growth in 
adults: sprouting angiogenesis, arteriogenesis, and vasculogenesis.  Sprouting 
angiogenesis is the best understood and most common mechanism and involves the 
growth of new microvasculature and capillary beds, usually driven naturally in adults by 
hypoxia or wound healing but is also activated in the growth of tumors.  Oxygen in tissue 
is monitored by hypoxia-inducible factor-1 (HIF-1), composing of alpha and beta 
subunits.  The HIF-1β subunit is relatively stable while the HIF-1α subunit is targeted for 
rapid degradation by the oxygen sensitive von Hippel-Lindau pathway.  At low oxygen 
levels HIF-1α degradation is impaired, leading to increased HIF-1 heterodimerization, 
DNA binding, and transcription of pro-angiogenic genes.  HIF-independent pathways 
also exist.  For example, peroxisome-proliferator-activated receptor-γ coactivator-1α 
(PGC-1α), a major regulator of mitochondrial function in response to exercise or low-
nutrient environments, is able to exert strong control over the vascular endothelial growth 
factor gene and induce angiogenesis [16]. 
In sprouting angiogenesis, new blood vessels are formed by sprouting and 
migration from existing capillaries.  A growth factor gradient initiates endothelial cell 
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activation. Migrating endothelial cells lead the growth of a new sprouting vessel by 
degrading the basement membrane and laying down a provisional extracellular matrix.  
Endothelial cells proliferate and form connections to neighboring vessels, develop 
lumens, and split existing vessels though a process known as intussusception, and remove 
extra branches in a process known as quiescence [17].  An intricate process of sprouting, 
branching, intussusception, and regression plays out to shape the ultimate pattern of a 
growing capillary plexus.  Following tubule formation, newly formed vessels are sealed 
by formation of endothelial cell-cell junctions and stabilized by addition of mural cells or 
pericytes and smooth muscle cells.  Sprouting vessels grow down gradients of VEGF and 
other factors, led by an endothelial tip cell, that is tuned to a variety of positive and 
negative signals coming from the surrounding matrix and other cells.  The process of 
sprouting angiogenesis is illustrated in Figure 2.1.  This process appears to be driven in a 
very similar way to neuron guidance, and many of the neural guidance proteins are being 
discovered to play pivotal roles in vascular morphogenesis [17-19].  The four major 
families of guidance proteins in neural and vascular sprouting are semaphorins, ephrins, 
slits, and netrins, along with their associated receptors.  The regulation of neural and 




Figure 2.1 Mechanisms of sprouting angiogenesis. (A) Endothelial cell is activated in 
response to a growth factor gradient, tip cell is selected. (B) Tip cell degrades basement 
membrane and migrates down gradient, following positive and negative guidance cues in 
the matrix, stalk cells form behind leading tip cell. (C) Guidance cues control pathfinding 
and morphogenesis, large vacuoles form in stalk cells and merge to make tubules. (D) 
Recruitment of pericytes and deposition of basement memebrane stabilizes newly formed 
endothelial tubules.  
 10 
The VEGF family of growth factors has been identified as critically important to 
angiogenesis and comprises several isoforms.  VEGF-A (commonly referred to as simply 
VEGF) is a potent stimulator of endothelial cell mitogenesis, cell migration, vasodilation, 
and a mediator of microvascular permeability.  Placental growth factor (PlGF), another 
potent VEGF isoform is capable of stimulating angiogenesis and collateral vessel growth 
while avoiding side effects common to VEGF such as edema and hypotension [20].  
While being a strong vascular stimulator, VEGF signaling primarily serves to drive 
expansion of the capillary bed, and it appears that VEGF administered alone has limited 
ability to induce the growth of larger vessels.  Long-duration exposure is necessary to 
produce stable microvasculature that does not resorb after withdrawal of the VEGF 
stimulus [21].  Because VEGF-driven angiogenesis does not consistently result in 
formation of functional, stable vasculature, VEGF therapy alone may not be the ideal 
treatment for increasing blood perfusion to an ischemic tissue [3, 22].  Administration of 
additional supporting growth factors such as FGF-2, angiopoeitins, PlGF, or PDGF [22] 
at the appropriate time point help to stabilize newly formed endothelial tubules by 
recruiting pericytes and smooth muscle cells, perhaps resulting in a more predictable 
therapeutic response. 
In contrast to ischemia-induced angiogenesis, arteriogenesis usually occurs 
proximally to the ischemic tissue and is often linked to atherosclerosis when it occurs 
naturally in adults, although the specific mechanisms are less well understood.  
Mechanical stresses at the site of arterial stenosis activate endothelial cells [23], 
upregulating expression of the monocyte chemoattractant protein-1 (MCP-1), FGF, 
PDGF, VEGF, MMP, cell-adhesion molecules, and nitric oxide (NO).  This mixture of 
factors promotes inflammatory and remodeling responses.  MCP-1 attracts monocytes 
that enter the vessel wall and differentiate to macrophages, producing inflammatory 
cytokines such as TNF-α.  Studies of hindlimb ischemia in animals indicate that 
arteriogenesis is more likely to occur by widening of existing vessels rather than 
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formation of new vessels [24], although this has not been confirmed for all situations.  
The process of arteriogenesis has the ability to increase blood flow to distal tissues 20-30 
times [11], a much larger volume of flow than possible by microvascular expansion.  A 
few large vessels are capable of delivering a much larger volume of blood than many 
small high-resistance capillaries according to the Poiseuille’s law [25], and as such, 
therapeutic vascularization should aim to develop these larger collateral vessels. At the 
same time, capillary formation cannot be ignored as it is crucial to improving 
oxygenation and gas exchange at the cellular level in ischemic tissues [25], and it may 
prove true that stimulation of both capillaries and collateral vessels is required for the 
best healing response. 
Vasculogenesis, once believed to only occur in the developing embryo, refers to 
the de novo generation of new vessels from the migration and differentiation of 
endothelial progenitor cells found in the bone marrow and in circulation.  Vasculogenesis 
in adults has been an area of intense study and controversy in the recent literature with 
conflicting studies published as to the sourcing and contribution of progenitors in the 
growth of new vessels.  Some evidence indicates that progenitor cells do not directly 
contribute to the endothelium and are located only perivascularly [26].  Nevertheless, a 
growing body of preclinical [27] and clinical trials [28, 29] indicates that transplantation 
of blood-derived or bone marrow-derived progenitor cells beneficially affects cardiac 
function after myocardial infarction as well as promotes neovascularization in ischemic 
tissue.  An increasingly well-characterized cell population expressing CD34 as well as 
other markers and considered to include a hematopoietic cell population is known as 
endothelial progenitor cells or EPCs.  These endothelial progenitors have the ability to 





Growth Factor Delivery 
The early phase I and II human clinical trials with VEGF, FGF, and hepatocyte 
growth factor (HGF) were promising, but larger randomized placebo-controlled trials 
failed to show significant benefits in the approved end-points.  One of the proposed 
problems associated with the limited success of early clinical trials is insufficient delivery 
or dosing of growth factors due to a short half life in the body.  Bolus injection of soluble 
growth factor, either systemically or locally administered by one of the classical delivery 
methods including intra-arterial administration, systemic administration (intravenous), 
and direct intramuscular injection, results in a rapidly depleted, poorly controlled delivery 
with the resulting vascular growth often disorganized, poorly functional, and transient.  
New studies are aimed at developing a better understanding of the specific concentration 
ranges, gradients, and exposure duration to elicit a more controlled angiogenic response. 
The dosage response of VEGF is highly sensitive: low doses result in increased 
vascular permeability and overdoses result in hemangioma formation [31] and fatal 
vascular leakage [31].  Most research shows that sustained stimulation with a high level 
of VEGF is required for formation of stable vasculature in vivo [32], but optimal dosing 
schedules remain unproven [33].  Researchers are investigating ways to regulate the 
exposure time [34] and local delivery dosage of angiogenic growth factors as well as 
optimize safe and effective dosages for use in humans.  In mice, VEGF dosages of 150 ng 
per day delivered by osmotic pump consistently induced high degrees of vascularization 
with vessels stable for at least 80 days after withdrawal of the growth factor [16].  
Vessels induced by higher concentrations of VEGF resorbed within 20 days of growth 
factor withdrawal while lower concentrations of VEGF failed to induce a high degree of 
vascularization.  Optimal dosing in human patients may be difficult to determine because 
physiologically relevant dosages can differ from animal models, and patients in need of 
angiogenic therapy may have an impaired angiogenic response due to various disease 
states and metabolic disorders whereas most animal models use healthy test subjects. 
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Besides dose response, scientists are also discerning the role of directionality and 
gradient in angiogenic signaling.  A microcarrier-based angiogenic sprouting assay, an 
effective in vitro screening technique [35, 36], was recently used to examine the effects 
of VEGF gradient and concentration on endothelial sprouting [37].  Endothelial cells 
seeded on microcarriers sprouted tubules aligned with VEGF presented in a gradient, 
with maximal alignment occurring in a 0 to 100 ng/mL gradient.  It was also seen that 
cells at the tip of the sprout bound significantly more VEGF then cells in the body of the 
sprout.  At very high VEGF concentrations, binding was saturated and sprouting 
directionality was lost.  This finding supports previous data that the tip cells of vascular 
sprouts aid in directionality and propagation of new microvessels down a growth factor 
gradient [38].  When translated in vivo to a hind limb ischemia model, scaffolds 
containing gradients of VEGF were better at restoring perfusion and avoiding necrosis 
than non-gradient controls.  It is thought that forces such as interstitial flow contribute to 
the formation of natural growth factor gradients in vivo and have been investigated for 
directing vascular morphogenesis [39-41].  When considered in the context of vascular 
architecture, gradient formation makes sense to drive directionality of vessel growth.  
Naturally derived vascular beds have an organized hierarchical structure while tumor 
vasculature is randomly organized.  Gradient delivery of growth factors may be a means 
of promoting better architecture in induced vascular beds. 
While VEGF and FGF have received much attention in the literature, PlGF may 
prove worthwhile to study in greater detail.  PlGF has been shown to be equally as potent 
as VEGF at promoting angiogenesis while also promoting arteriogenesis [42].  PlGF 
actually promotes increased expression of VEGF in ischemic tissue and its effects are 
increased when administered in synergy with VEGF [43].  Notably, PlGF may be a better 
candidate for arteriogenic therapy than FGF or PDGF which preferentially recruit either 
endothelial and mural cells or inflammatory cells, respectively, while PlGF can recruit all 
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three cells types on its own.  All three cells types are cited as required for arteriogenesis 
[44]. 
In contrast to bolus growth factor deliver, it has shown that controlled growth 
factor release, given correct dosage and exposure time, is highly beneficial to inducing 
the growth of functional vasculature in animal models of ischemia [45, 46].  Stabilization 
and molecular regulation of nascent blood vessels is also critical to achieving a correct 
angiogenic response [47].  Uncontrolled delivery of FGF or VEGF usually results in 
unstable vessel growth that resembles immature tumor vasculature [48].  Tumor vessels 
are chaotic and do not follow the hierarchical branching pattern of normal vascular 
networks [14, 47].  Several novel approaches are under investigation to more precisely 
regulate the spatial temporal presentation of the right combination of factors to induce 
more appropriate vessel architecture and stability [49].  One such approach is the design 
of polymeric scaffolds that stagger exposure to two or more growth factors such as VEGF 
and PDGF [49, 50], FGF and HGF [51], or VEGF and angiopoietin-1 [52] to create more 
stable vessels with regular architecture by more closely mimicking the biological 
mechanism of vessel induction followed by stabilization.  Many other stabilization and 
growth “on” and “off” signals exist, including activators and inhibitors of the Wnt and 
Notch pathways [53] and neural guidance cues (netrin, ephrin, etc).  More research is 
needed in the area of branching morphogenesis [54] to solve the intricate programming 
structure of vascularization. 
A different approach to single or multiple staggered growth factor delivery is to 
induce the expression of upstream activators of a large number of angiogenic regulators 
such as HIF-1α.  Because HIF-1α is naturally degraded, a number of techniques have 
been employed to ensure its stabilization in vivo.  Delivery of the gene for a 
physiologically stable HIF-1α/VP16 fusion protein has been shown to promote recovery 
of peripheral limb ischemia in animals [55, 56] and was recently tested in a phase I trial 
with a percentage of patients with peripheral limb ischemia showing pain resolution and 
 15 
ulcer healing [57].  Another method for HIF-1α stabilization is expression of a mutant 
HIF-1α that lacks an oxygen degradation domain [58].   
There are certain disadvantages to delivering recombinant proteins, included a 
short half-life in vivo and expense and difficulty in manufacturing.  Scientists have 
investigated using gene therapy to deliver a more prolonged and targeted delivery of 
angiogenic growth factors.  Both viral and nonviral vectors have been tested clinically for 
delivery of angiogenic factors, with results similar to those seen by delivering growth 
factors.  Because of safety concerns with viral vectors, nonviral vectors are initially more 
attractive for human use.  However nonviral vectors are generally less efficient at 
inducing expression.  Novel gene therapy delivery mechanisms are focused on improving 
nonviral vector delivery.  Electroporation has recently been used to deliver cDNA for 
HIF-1α to improve wound healing in elderly diabetic mice [59].  Other delivery 
mechanisms such as liposome complexes [60] are under investigation to improve 
delivery of nonviral vectors and have been tested preclinically for delivery of 
angiogenesis related genes.  Delivery of VEGF activating transcription factors is also 
under investigation [61, 62].  The concept of engineered cell therapy has been proposed 
as a solution to problems with direct gene therapy and is briefly discussed further on in 
the next section. 
 
Cell Therapy 
Another approach to treating ischemic disease and promoting angiogenesis is the 
transplantation of autologous cells which has been studied in large animals [27, 63] and 
in clinical trials [28, 29].  Some of the cell sources under investigation include bone-
marrow stromal cells, mesenchymal stem cells, and endothelial progenitor cells.  A 
number of trials under development and currently ongoing will test the safety and 
efficacy of autologous cell transplantation in a variety of ischemic diseases.  Some of the 
early cell transplantation trials used skeletal myoblasts and had mixed results at treating 
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ischemic heart disease [28, 64-66], this may be due to a reduced ability of myoblasts to 
promote neovascularization and re-perfusion.  Transplantation of less-differentiated cell 
types such as marrow-derived stromal cells, vascular/endothelial progenitor cells, and 
mesenchymal stem cells, may lead to a stronger healing response.  Transplantation of 
endothelial progenitor cells has shown success in treating peripheral limb ischemia by 
promoting collateral vessel formation in both humans and animals [67, 68], as well as 
treating myocardial ischemia [69, 70].  Transplanted mesenchymal stem cells and bone 
marrow stromal cells promote wound healing through differentiation and release of pro-
angiogenic factors [71].  Endothelial progenitor cells have also been studied for 
improving bone regeneration and healing [72].  Current myocardial delivery mechanisms 
for cell-based therapy that have proven somewhat effective include intracoronary and 
intramyocardial delivery [8].  The population of endothelial progenitor cells found in the 
bone marrow, circulation, or other tissues, first isolated primarily by Asahara and 
colleagues in 1997 [73], is one of the most promising cell sources due to their 
regenerative capacity and ability to home to sites of ischemia and shown promising 
functional recovery in animal models [74] and human trials [75, 76].  One comparative 
study between mesenchymal progenitors and endothelial progenitors for myocardial 
infarct regeneration showed better neovascularization and contractility for treatment with 
endothelial progenitors over mesenchymal [77].  Endothelial progenitor cells (EPC) can 
be mobilized to circulation from the bone marrow by administration of granulocyte 
colony stimulating factor (G-CSF) and home to sites of ischemia, inflammation, and 
biomaterials with artificial EPC capturing motifs [78]. EPC are an intriguing cell type for 
treating ischemic conditions that are described in greater detail in [30, 79].  Stem cell 
homing has also been investigated for gene delivery [80]. 
An alternative to delivering cells directly is administration of cytokines that 
attract progenitor cells to sites of ischemia.  After myocardial infarction there is a 
mobilization of bone marrow-derived stem/progenitor cells to the circulation [81, 82].  
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Clinical trials investigating the use of granulocyte-colony stimulating factor, a cytokine 
shown to promote the mobilization of bone marrow stem/progenitor cells and subsequent 
accumulation in ischemic tissue, have so-far failed to demonstrate significant beneficial 
effects in the ischemic heart [83-85].  However, other techniques are underway to capture 
or home endothelial progenitors to sites of ischemia.  Systemic administration of anti-α4 
integrin antibody was recently shown to promote the mobilization and functional 
incorporation of bone-marrow endothelial progenitor cells [86], in a method that mimics 
observed downregulation of α4 integrin in natural progenitor cell mobilization [87, 88].  
Asahara and colleagues recently discovered a key piece of the endothelial progenitor 
homing puzzle, showing that specific Jag-1-derived Notch signaling is required for 
endothelial progenitor-mediated vasculogenesis [89], although much work remains to be 
done in this area.  According to a recent review article, endothelial progenitors hold much 
promise for treatment of ischemic disorders, and better techniques for cell isolation, 
expansion, mobilization, recruitment, and transplantation are under development [90]. 
Engineered cell therapy is one prospective method to resolve problems related to 
direct gene delivery in humans.   Engineered cell therapy to promote vascularization is 
growing in popularity and has been used to deliver non-naturally secreted proteins to the 
heart [91-93] and for delivery of VEGF in tissue-engineered bone repair scaffolds [94]. 
Cell transplantation is also being investigated as a means of vascularizing tissue 
engineered constructs.  Several examples have been published of microvascular tubules 
forming in implanted constructs containing endothelial cells.  The most successful 
constructs, in terms of linkage to host vasculature, vessel architecture, and vessel 
longevity, include at least two cell types in an appropriate matrix that allows for cell 
migration and promotes the endothelial cell phenotype.  A particularly successful model 
constructed by Jain et al. [95] incorporated a co-culture of human umbilical vein 
endothelial cells (HUVEC) and 10T1/2 mesenchymal precursor cells in a fibronectin-type 
I / collagen gel implanted in a mouse.  Patent vasculature connected to the host 
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circulatory system was formed that was stable for at least a year and was responsive to 
the vasoconstrictor endothelin.  In other studies, human dermal microvascular endothelial 
cell spheriods and preadipocytes were transplanted into a fibrin matrix on a chick 
chorioallentoic membrane [14] and fibroblast sheets co-cultured with endothelial 
progenitors were shown to improve cardiac function in infracted hearts [96].  In these 
examples the transplant formed a patent microvasculature connected to the host system 
without exogenous angiogenic growth factors or transient transfection.  Incorporating 
appropriate autologous cell types in well-designed matrices may prove a safe and 
effective means of vascularizing tissue engineered implants, and has been used for 
developing engineered vascularized skeletal muscle [97]. 
 
Matrix Interaction 
Much progress has been made towards the development of vascular-inductive 
tissue engineering matrices.  Early work in this area involved passive adsorption or bulk 
incorporation of growth factors in porous or degradable scaffolds.  While somewhat 
effective at producing initial vascular growth, quick release profiles and rapid diffusion 
of growth factors do not result in the desired response of functional, stable vasculature.  
Researchers are investigating covalently tethering growth factors to matrices and 
incorporating growth factor release mechanisms tied to angiogenic activity such as matrix 
metalloproteinase (MMP)-degradable sites [98, 99].  In addition to growth factors, 
extracellular matrix proteins that regulate factors such as cell adhesion and migration 
have an impact on cell function and gene regulation.  Different extracellular matrix 
proteins and ligands have been shown to modulate the angiogenic response [100], often 
through integrin activation [101, 102].  Recent research has taken an integrative approach 
to combine angiogenic growth factors with the appropriate matrix signals to create 
controlled biomimetic analogs to natural extracellular matrices. 
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A new generation of bioactive materials is under development, designed to more 
closely mimic the natural extracellular matrix while providing greater control over the 
cellular response [103]. Fibrin matrices loaded with a modified version of VEGF that 
directly binds fibrin and is subsequently locally released in a proteolytic-dependent 
manner have been shown to induce local and controlled blood vessel growth in animal 
models [104, 105].  Recent advances have been made in the design of bio-artificial 
matrices, or artificial scaffold materials that incorporate bioactive motifs, illustrated in 
Figure 2.3.  Conjugation of bio-adhesive signals such as the integrin-binding peptide 
RGD to surfaces of artificial materials has long been established.  Hubbell and West have 
succeeded in developing 3D artificial matrices that incorporate adhesive signals as well 
as growth factors such as VEGF [105, 106] and epidermal growth factor [107].  The 
concept of a bio-artificial matrix is attractive because it allows the presentation of a 
controlled and tailored environment.  In the case of a polyethylene glycol (PEG) –based 
matrix, intrinsically resistant to non-specific protein adsorption and cell adhesion, 
biofunctionality can be built onto a “clean-slate” background material.  This system can 
be used to test the functionality of diverse proteins in a controlled environment such as 
ephrin which was shown to promote the formation of endothelial tubules without 
additional adhesive signals [108].  Another attractive element of bioartificial matrices is 
the ability to spatially control presentation of bioactive ligands with fine precision.  Photo 
patterning techniques have been utilized to construct 3D patterned matrices [109-111].  
Geometric constraints such as line width have been shown to effect formation of 
endothelial tubules [112].  In theory, photopattening techniques could be used to control 
the architecture of a vascular network and has been investigated on 2D surfaces by our 
laboratory. 
The concept of photopatterning guidance channels mimics the natural 
phenomenon of vascular memory. Figure 2.2 illustates the concept of photopatterning 
adhesive ligands against a non-adhesive polyethylene glycol background. Vascular 
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memory, important to the study of tumor angiogenesis, occurs when regressed 
microvasculature leaves behind empty sleeves of basement membrane and associated 
pericytes [113].  When conditions permit revascularization, such as reversal of anti-
VEGF therapy, a rapid repopulation of vessels along basement membrane sleeves is 
observed [113, 114], similar to the way nerves regenerate along pre-existing pathways 
[115].  Vascular memory has also been noted to occur in normal human vasculature [116, 
117].  Future study of vascular and neural pathfinding in development and healing will 
undoubtedly produce future medical benefits. Promising results from combination 
therapies co-delivering [118] or time-release staggering multiple growth factors [49] 
support the idea that a robust vascular healing response requires coordination of the 
correct signaling factors, dosing, and exposure time points.  Incorporation of biomaterial 
delivery vehicles aims to solve some of the complex pharmacokinetics, but this approach 
is ultimately hindered by a lack of knowledge of optimal dosage and timing and the 
inability of delivered signals to override the “background noise” of a pro-inflammatory 
environment.  Research into “master switch” upstream activators such as HIF-1α [56, 
119] that activate an entire pro-vascular signaling cascade are an exciting direction to the 
growth factor delivery field. But even if regenerative medicine can one day fully 
recapitulate the pharmacokinetics of an endogenous healing or developmental 
vascularization response, ultimately the question arises as to why the natural healing 
mechanisms failed to begin with or in the case of myocardial infarction, why no native 
regenerative repair process occurs at all. Various disease states, aging, and scar-tissue 
formation are obvious blockades to natural endothelial repair mechanisms, and growth 
factor signaling alone may be an intrinsically limited strategy when delivered in the 
context of diseased or non-healing tissue [120]. 
New approaches to treating ischemia are focusing on delivery of regenerative 
cells alone (Fig. 2.3B) and in combination with growth factors and biomaterial scaffolds 
(Fig. 2.3E).  For cell therapy, we are beginning to understand the importance of 
 21 
delivering multiple progenitor cell-types in creating functional tissues. Advances in gene 
and cell delivery techniques have yielded astonishing results in animal models such as 
polymeric nanoparticle gene delivery vehicles combined with human embryonic (hEST) 
and mesenchymal stem cells (MSC) that showed significant vascularization and 




Figure 2.2 UV photopatterning of PEG-DA hydrogel. (A) RGD-FITC is covalently 
tethered to a PEG hydrogel matrix in a honeycomb pattern by UV activation of 
photoinitiator through a mask onto a pre-cast gel disc. After a wash step lines are visible. 
(B) Using gels patterned in this technique, fibroblasts seeded on the gel surface form a 
spread monolayer, remain rounded, or align to the adhesive ligand. 
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While current tissue engineering approaches aim to overcome the native tissue 
dysfunction by delivering effective regenerative cells in conjunction with the appropriate 
matrix and signaling molecules, the monumental challenge of integrating engineered 
tissues with the host vasculature remains significant.  The challenge of clinically 
delivering functional and vascularized large-scale tissue substitutes creates a ‘chicken-or-
the-egg’ paradox. Is a functional vasculature required before regenerative cells can be 
transplanted, or are the regenerative cells needed to give rise to the new vasculature 
simultaneously as functional tissue develops?  Researchers must attempt to either: 
connect and perfuse a pre-fabricated functional critical-sized tissue, form a pre-
vascularized site and subsequently add in functional tissue, or simultaneously form 
vasculature alongside functional tissue. 
From the standpoint of in situ tissue formation, tissue engineering research has 
progressed to the point of predictably and repeatedly producing patent, stable vasculature 
in a variety of animal models through transplantation of a combination of endothelial and 
mesenchymal cells or progenitors encapsulated in biological extracellular matrix (ECM) 
[95] and Matrigel™ implants [122].  The driving force behind this advancement is a 
mimicry of embryonic vasculogenesis where angioblasts and mesenchymal stem cells 
organize into a network to form a pericyte-stabilized capillary bed [123].  The ability to 
recapitulate this capillary network formation using adult cells obtained in routine 
sampling procedures of the blood and bone marrow represents a useful and feasible pool 
from which to further develop clinically relevant vascularized tissue constructs.  
Matrigel™, a decellularized matrix derived from mouse sarcoma cells, has been a 
common component for both in vitro endothelial tube formation and in vivo 3D network 
vascularization. However, Matrigel™ is a poorly controlled and highly uncharacterized 
environment from an engineering perspective, containing a mélange of growth factors 
and matrix-associated bioactive signals.  Unfortunately, because of its tumoral and 
xenogenic origin, Matrigel™ is ultimately not an optimal choice for development of 
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clinically-relevant therapies. Major effort is being concentrated on development of fully 
synthetic or well-defined biological matrices with potent pro-angiogenic properties 
manifested either through encapsulated co-culture systems of endothelial and 
mesenchymal cells or cell-free smart materials (Fig. 2.3C) directly recruiting vascular 
ingrowth from the surrounding host tissue. 
Novel vascular-inductive biomaterial systems include schemes for directly 
conjugating growth factors to a degradable matrix and releasing them in a cell-demanded 
manner.  One such system that has shown promising results incorporates bioactive 
ligands into a synthetic polyethylene glycol (PEG) hydrogel.  PEG hydrogels for 
vascularization have been developed with different crosslinking reaction schemes.  
Popular renditions include 4-arm PEG-vinyl sulfone (PEG-4VS) crosslinked by Michael-
type addition [124] and PEG-diacrylate (PEG-DA) crosslinked by photoinitiated free-
radical polymerization [125].  Both systems are functionalized with protease (MMP)-
cleavable peptide sequences, domains for cell adhesion (RGD peptide), and tethered 
growth factors.  These PEG-based matrices have been used to promote both in vitro [126] 
and in vivo [125, 127] vascular network formation from encapsulated cells or vessel 
ingrowth from the surrounding tissue. These engineered matrices that directly bind 
growth factor and release it in a proteolytically-dependent or “on-demand” manner 
induce more stabilized and longer-lasting vasculature compared to diffusive growth 
factor release.  However, even these induced stabilized vessels are reported to regress in 
time in the absence of true physiological demand [124]. Yet another promising artificial 
matrix idea utilizes self assembled peptide amphiphile nanofibril matrices with heparin 
sulfate binding sites to present bioactive ligands and growth factors to promote de novo 
subcutaneous vascularization [128]. Research in engineered matrices has progressed for 
tissue engineering models including cardiac progenitor differentiation [129], pancreatic 
islet encapsulation [130], and epithelial morphogenesis [131].  We can expect future 
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research to combine engineered vascular-inductive matrices with repair or replacement of 
metabolically active tissues in vivo. 
An alternative strategy to inducing vascular organization into a scaffold is to 
fabricate vascular conduits directly prior to implantation (Fig. 2.3D). Several clever 
engineering techniques to generate endothelial-lined channels in tissue engineered 
constructs have emerged.  One simple yet effective technique involves close-packed 
modular cylindrical collagen matrices coated in endothelial cells to generate endothelial 
lined channels in a random packed array.  These channels remodel in vivo to generate a 
vascularized graft [132].  Another self-assembly technique uses microtissue building 
blocks made from human artery-derived fibroblasts coated with human umbilical vein 
endothelial cells (HUVEC) to mold a small diameter vascular graft with high levels of 
ECM deposition [133].  In theory, such a system could also be used for inducing 
vascularization of a tissue-engineered construct. Cell sheet technology is another vascular 
design technique that employs a process of alternatively stacked monolayers of HUVEC 
and myoblasts to create highly vascularized implants of myoblasts in vivo with robust 
endothelial networks [134].   
Developing along-side the effort to create clinically-useful and well-characterized 
pro-vascular matrices are approaches to merge this technology with relevant tissue-
specific replacement models.  For example, pancreatic islets are highly vascularized 
spherical clusters of endocrine cells in the pancreas which include the insulin producing 
β-cells.  Islet transplantation is a promising therapeutic option with freedom from 
exogenous insulin injection for type-1 diabetes, yet current transplantation techniques are 
severely limited due to high islet morbidity associated with poor engraftment and 
reperfusion.  Current efforts to improve islet transplantation therapy include gene therapy 
to overexpress angiogenic growth factors [135, 136] in transplanted islets and seeding of 
islets into pre-vascularized Matrigel™ [137] and collagen [138] implants. 
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Engineering mechanically sound and functional cardiac tissue for the repair of 
myocardial infarction and associated ischemic heart disease, the leading cause of death in 
developed countries, is one of the most promising and grand targets for tissue 
engineering.  Progress in development of engineered cardiac tissue has not always 
addressed the need for vascularization and engineered tissues suffer from necrotic cores 
and little or no integration with the host tissue [139].  Incorporation of HUVEC and 
mouse embryonic fibroblasts (MEF) in cardiac patches leads to a strong vascular network 
formation in vitro and which, if formed preceding implantation in rat heart tissue, shows 
vastly improved integration and perfusion than patches without HUVEC and MEF [139, 
140]. Taking the process one step further, neonatal cardiac cell patches containing 
angiogenic factors pre-vascularized for 1 week in the omentum and subsequently 
transplanted into infracted heart tissue showed improved structural, electrical, and cardiac 
output over non-vascularized controls [141]. Alternatively, microvascular segments 
stabilized in collagen and transplanted into ischemic myocardium formed vascularized 
cardiac patches with improved left ventricular function [142]. 
Finally, the most direct approach to providing the necessary cues and allowing 
cells and tissues to control the ultimate shape of the engineered tissue and associated 
vasculature is direct fabrication of functioning tissue. Technologies to exert spatial 
control over the placement and organization of individual cells and tissue microstructures 
include 3D tissue printing [143, 144] and lithographic fabrication [145, 146] of vascular-
inductive matrices have emerged as viable options.  Microfluidic devices are also 
becoming employed to create controlled in vitro systems for studying underlying 
mechanisms and testing new ideas [147]. 
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Figure 2.3 Strategies for inducing vascularization in engineered tissues. (A) Growth 
factors such as VEGF and bFGF as recombinant proteins or gene vectors.  EPC-
mobilizing cytokines such as G-CSF (B) Progenitor cells such as EPC and MSC 
(C) Biomaterials such as bioactive PEG hydrogels (D) Vessel conduits or endothelium-
lined channels directly fabricated into an implant (E) Combination therapies such as 




Some novel unconventional approaches have been proposed to increase vascular 
perfusion in ischemic tissue.  Scientists looking for new approaches have been driven 
mainly by technical difficulties in delivering pro-angiogenic factors locally to ischemic 
tissue for sufficiently long periods of time, the often confounding requirements for 
multiple factors delivered in the right spatial and temporal dosage, and the risk of 
undesirable side effects from systemic administration of angiogenic factors.  One novel 
approach capitalizes on a large body of research which implicates nitric oxide (NO) as a 
stimulator of angiogenesis [148-150].  NO increases the expression of VEGF and other 
angiogenic factors, recruits pericytes, and improves blood perfusion by inducing vessel 
dilation.  NO can also protect tissue against ischemic damage by reprogramming the 
cell’s metabolism to tolerate a lower oxygen environment through nitrosylation of 
oxygen sensor PHD1 proteins and complex I proteins in the electron-transfer chain to 
reduce the generation of pro-inflammatory reactive oxygen species.  It is important to 
note that in higher concentrations, or in certain physiological conditions NO can have the 
opposite effect.  Kumar et al. demonstrated the use of nitrite (NO2-) as a pro-angiogenic 
molecule, considering the fact that nitrite is reduced to NO in ischemic conditions but is 
oxidized into harmless nitrate (NO3-) in oxygenated tissue [151].  They showed that 
administration of sodium nitrite by I.P. injection significantly restored ischemic hind limb 
blood flow, vascular density, and endothelial cell proliferation.  Administration of 
carboxy PTIO, a NO scavenger, abolished the positive effects, bolstering their argument 
that NO is responsible for the changes.  These results are exciting because they open the 
possibility of an effective, yet inexpensive treatment option with few side effects and 
simple administration options allowing for long-term treatment. 
Traditional angiogenic factors such as VEGF and FGF stimulate vascularization 
but do not promote additional metabolic changes [152].  Recent studies are solidifying 
the link between metabolic demand for oxygen and angiogenesis.  Expression of the 
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transcriptional coactivator peroxisome proliferator-activated receptor-γ coactivator 1α  
(PGC-1α), a potent metabolic sensor and regulator, is induced by a low-nutrient and low-
oxygen environment such as during aerobic exercise training.  PGC-1α was recently 
shown to be a potent stimulator of VEGF expression angiogenesis in ischemic tissues but 
does not involve the traditional HIF-1 pathway [153].  Activating the PGC-1α pathway 
may be a novel method of inducing angiogenic response.  Another interesting idea is to 
induce tolerance of a hypoxic environment to stave off tissue damage and necrosis after 
an infarction [154], allowing time for a subsequent pro-angiogenic therapy to take effect.  
Aragonés et al. show that prolyl hydroxylase 1 (Phd-1), an oxygen-sensitive enzyme that 
controls the stability of HIFs, plays a key role in regulating metabolism and reducing 
oxygen requirements in muscle tissue [154].  While it might seem counter-intuitive to 
induce hypoxia tolerance, as Phd1-null mice showed reduced exercise performance, the 
benefit lies in reducing damage.  Oxidative consumption under hypoxic conditions has 
been linked to generation of reactive oxygen species, and limiting oxygen consumption 
when oxygen levels are low leads to less cell death [155].  Another potential metabolic 
control involves the experimental concept of ischemia preconditioning where tissues are 
rendered resistant to ischemia/reperfusion injury, and was first shown to result in 
reduction of myocardial infarct sizes in 1986 [156].  Ischemia precondition is 
traditionally induced by brief repeated episodes of coronary artery occlusion prior to a 
major prolonged occlusion.  New research has shown that ischemic preconditioning 
results in a robust activation of HIF-1α and that pretreatment with the HIF activator 
dimethyloxalylglycine or selective siRNA repression of prolylhydroxylase-2 resulted in 
cardioprotection similar to that of traditional ischemic preconditioning [157].  One could 
imagine a treatment scenario where hypoxia tolerance is initially induced, followed by 
switching on angiogenesis mechanisms and gradually restoring oxygen consumption 
back to normal levels as the tissue is revascularized.  These new studies show that 
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targeting oxidative metabolism and capitalizing on its natural link to angiogenesis is a 
valid and novel therapeutic tool for treating ischemic disease. 
 
Methods for validation and analysis of vascularization techniques 
It is important to measure and validate the architecture and function of induced 
vasculature. Induced vasculature often has little resemblance to native tissue architecture, 
and has the potential to look and behave like tumor vasculature [47]. Furthermore, 
induced vasculature may suffer from poor perfusion and functionality. Several robust 
analysis strategies have been developed for both in vivo and in vitro models [158]. 
In vitro analysis techniques: Three dimensional culture of endothelial cell types or 
co-culture of endothelial and mesenchymal progenitors (MSC or 10T1/2 embryonic 
fibroblasts [95]) will self-organized to form tubule networks in pro-vascular 
environments [158]. The addition of a mesenchymal cell type serves to stabilize the 
endothelial tubes.  Furthermore, if these cell types are cultured on the surface of 
microcarrier beads that are encapsulated in the matrix, endothelial tubes sprout from the 
beads [35, 158].  These bead-initiated sprouts can be easily quantified for number, length, 
and branching and used as a screening and analysis tool.  Three dimensional tissue 
culture of small sections of aorta from rat or mouse also sprout endothelial tubes from the 
aortic tissue in pro-vascular environments and are an alternative to single cell culture 
[159].  Lastly, the chorioallantoic membrane (CAM) is a vascularized membrane on 
developing chicken embryos that is widely used as a pseudo-in vivo system for testing 
vascularization effects [158]. 
In vivo analysis techniques:  Traditionally, histological techniques including 
lectin- and immuno-staining have been used to quantify induced vascularization in vivo. 
Three-dimensional architecture and function (vessel perfusion) are key measures that are 
difficult to determine from histological sections. One highly effective technique for 
quantitative analysis of three-dimensional vascular architecture is perfusion with the 
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silicone rubber radio-opaque injection compound Microfil ® (Flow Tech, Inc.) to create a 
cast of the vasculature. The vascular cast can then be scanned in three dimensions at high 
resolution (sub 10 μm) with microCT and analyzed with a number of algorithms for 
density, branching, and connectivity [159, 160].  One drawback to the microCT method 
is that it is a terminal procedure. Development of vasculature over time in live animals 
can be observed by intravital microscopy with window-models and dorsal skin-fold 
chambers [158]. Blood flow to ischemic limbs can be observed in live animals over time 
by laser Doppler perfusion imaging [127] (Moor Instruments) or with GFP-cells [158] 




The therapeutic vascularization field experienced initial setbacks in the failure of 
several clinical trials with growth factor therapy going quickly from benchtop to bedside 
before precise delivery methods and controls were elucidated.  A growing body of 
evidence is beginning to suggest that single growth factor therapy may be insufficient for 
restoring a large volume of blood flow to an ischemic tissue, especially in a diseased state 
where vessels may be less responsive.  A great deal of effort has gone into identifying 
upstream activators that induce expression of multiple angiogenic factors as well as 
alternative pathways to the traditional angiogenic signaling paradigm.  Cell-based therapy 
looks very promising, but continues to suffer from optimal sourcing and delivery 
strategies.  A new generation of therapies is needed to better address the problems with 





Future Perspective:  
Future approaches to therapeutic vascularization will have a better chance of 
success if a more targeted and careful approach than that of earlier trials is utilized.  A 
clinically successful vascularization therapy is likely to be a combination therapy.  
Examples of combination therapies such as engineered cell therapy, multiple growth 
factor release, or growth-factor/cell/matrix combinations [161] are beginning to emerge.  
We must also consider the importance of inducing arteriogenesis, angiogenesis, 
neovascularization, or some combination.  Future therapies need to consider the end-goal 
in terms of re-perfusion and what type of therapy or combination strategy is best-suited to 
obtain both the necessary increase in blood-flow volume as well as ability to deliver 
oxygen.  Ongoing research is helping us to understand the complex signaling and 
pathfinding mechanisms that lead to branching morphogenesis.  Knowledge divulged 
from studies on development of vascular architecture and pathfinding, such as growth 
factor gradients, vascular memory, and morphogenesis signaling, needs to be applied to 
create more physiologically accurate and better functioning induced vasculature.  More 
work is needed to sort out the extremely complex angiogenic molecular program.  
Metabolic control over angiogenesis is an interesting new approach and further research 
in this area may provide alternative therapies to patients who do not respond to traditional 
growth factor therapy or that have metabolic disease-related ischemic disorders.  
Additionally, advances in engineered bio-artificial and bio-active matrices are illustrating 
higher levels of control in tissue engineering and regenerative medicine, paving the way 
towards large-scale engineered tissue substitutes.  As work progresses in all of these 
areas, we can expect more functional therapies to become available to patients.  Based on 
the impressive progress thus far, we can predict that the future of therapeutic 
vascularization is quite bright. 
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Type 1 diabetes mellitus and islet transplantation therapy 
 One in every 400 to 600 children and adolescents suffer from type 1 diabetes 
mellitus T1DM [162], a condition that results from the autoimmune destruction of the 
insulin-producing beta cells in the pancreas. Left untreated, T1DM is a fatal disease. The 
discovery of insulin was a major medical breakthrough, for which Frederick Banting and 
John Macleod were awarded the 1923 Nobel Prize in medicine [163]. Subsequent 
developments in exogenous insulin therapy, blood sugar testing, and lifestyle adjustments 
allow type 1 diabetics to lead long and generally healthy lives. However, treatment is 
often burdensome, and complications associated with poor blood sugar regulation may 
lead to seizures or episodes of unconsciousness and long term organ damage. 
 
"This disease controls our lives with all the pricking of the fingers, shots, high 
and low blood sugars; it's like being on a seesaw. Without a cure, we will be 
stuck on this seesaw 'til the day we die." - Tre Kawkins, age 12 [164] 
 
For years the holy grail of T1DM research has been a self-regulating insulin 
source that can maintain blood sugar levels without regular patient monitoring, allowing 
the patient to live a more normal life. A large focus of research has been on implantable 
insulin pumps with glucose sensor feedback loops. While insulin pump improvements 
have been steady, the glucose sensors and pump leads suffer from attack by the innate 
immune response and must be repositioned regularly [165]. 
 Alternatively, whole pancreas or islet cells can be transplanted and serve as a 
biological source of insulin. Grafted islets or whole pancreas are often introduced at the 
same time as a kidney transplant. The need for immunosuppressive therapy for the kidney 
allows little additional risk to the patient to also transplant an insulin source. Islet cell 
transplantation is expected to be less invasive than a whole pancreas transplant and does 
not put the working digestive functions of the existing pancreas at risk. While still highly 
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experimental, islet cell transplant surgery has progressed to the point that 58% of patients 
in one study [166] were insulin independent at one year after islet cell transplantation. 
The current method of islet transplantation involves infusing donor islets into the 
recipient’s hepatic portal vein where they become lodged in the vascular system of the 
liver. While short term outcomes are promising, patients with islets grafted in this manner 
have a relatively poor long-term outcome: only about 10% of islet cell transplant 
recipients maintain exogenous insulin independence at 5 years [167-170]. Islet 
transplantation therapy in its current form is significantly limited by inadequate islet 
supply and mass, instant blood-mediated inflammatory reaction (IBMIR) [163], toxic 
responses to immunosuppressive drugs, and loss of islet viability/function during 
isolation and following implantation, particularly due to inadequate vascularization of the 
transplanted islets [171, 172]. It has been proposed that by delivering pancreatic islets in 
biologically active materials engineered to elicit a vascular-inductive response, 
significant improvements in the vascular connectivity of transplanted islets and 
subsequently the overall viability and graft success can be achieved[173, 174]. 
 Blood flow to pancreatic islets is central to islet function [175]. Pancreatic islets 
have higher densities of blood vessels compared to the surrounding exocrine tissue and 
receive 15-20% of pancreatic blood supply despite comprising only 1-2% of pancreas 
mass [176]. A dense network of capillaries maintains blood perfusion through the islet 
cell mass itself. In fact, it has been shown that nearly every insulin-producing beta cell 
neighbors an endothelial cell [177]. Our preliminary work has been successful in imaging 
the intra-islet capillary bed. Following islet isolation and transplantation, the re-
establishment of blood flow to islets requires several days and involves angiogenesis and 
possibly vasculogenesis. New blood vessel growth is often chimeric with endothelial 
cells arising from both the host tissue and the islets themselves [178]. In addition to 
ischemic conditions during this revascularization period, the resulting vasculature 
exhibits lower vessel density and lower oxygen tension than the native pancreas [179, 
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180]. Studies have shown that transplanted islets have reduced blood flow overall 
compared with native islets [135, 136, 176, 177, 181-184]. This inadequate 
revascularization of transplanted islets is a major cause for reduced islet viability, 
function, and engraftment [185-187]. Delivery of pro-vascularization factors, mostly via 
genetic manipulation of islets, has been shown to improve vascularization and islet 
function[135, 182-184, 188-190], but these strategies are hindered by insufficient and/or 
complex release pharmacokinetics and inadequate delivery matrices as well as technical 
and safety considerations associated with gene transfer. It has been proposed that optimal 
formation of a fully functional islet vasculature will require precise control of the timing, 
dose, and duration of angiogenic factor action [176]. VEGF-A, a potent angiogenic 
factor, has been shown to be a primary driver for islet vascularization in development, 
maintenance of the intra-islet capillary bed, and islet graft revascularization [177, 184, 
191]. Islets in VEGFloxP mice lacking expression of VEGF-A in the pancreas have 
severely limited islet capillary perfusion and reduced insulin output and glucose 
responsiveness [177]. 
 
Bio-functionalized PEG hydrogel 
Over the past 10 years, much progress has been made towards the development of 
vascular-inductive tissue engineering matrices. Early work in this area involved passive 
adsorption or bulk incorporation of growth factors in porous or degradable scaffolds. 
While somewhat effective at producing initial vascular growth, quick release profiles and 
rapid diffusion of bolus delivered growth factors do not result in the desired response of 
functional, stable vasculature [127]. Current research is more focused on sustained 
delivery of growth factors tethered to matrices, sometimes incorporating growth factor 
release mechanisms tied to angiogenic activity such as matrix metalloproteinase (MMP)-
degradable sites [98, 99]. In addition to growth factors, extracellular matrix proteins that 
regulate factors such as cell adhesion and migration have an impact on cell function and 
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gene regulation. Different extracellular matrix proteins and ligands have been shown to 
modulate the angiogenic response [100], often through integrin activation [101, 102]. 
Recent research has taken an integrative approach to combine angiogenic growth factors 
with the appropriate matrix signals to create controlled biomimetic analogs to natural 
extracellular matrices. 
The concept of a PEG-based bio-artificial matrix is attractive for cell 
transplantation therapy because it allows for the presentation of biologically active cues 
in a highly controlled and tailored environment. Because PEG is intrinsically resistant to 
non-specific protein adsorption and cell adhesion, biofunctionality can be built onto a 
“clean-slate” background material with tunable material properties such as pore size and 
mechanical stiffness [192]. Artificial biomimetic matrices usually contain mechanisms to 
allow for tissue or cell invasion, usually achieved through adhesive protein attachment / 
incorporation and either porous structure or degradable cross-links in the case of hydrogel 
systems . The PEG hydrogel lends itself well to examining the biofunctionality of diverse 
proteins and peptides in a controlled environment. Another attractive element of PEG-
based bioartificial matrices is the ability to spatially control presentation of bioactive 
ligands with fine precision. Photo-patterning techniques have been utilized to construct 
3D patterned matrices [109-111] and geometric constraints such as line width have been 
shown to effect formation of endothelial tubules [112, 193]. 
The usefulness of RGD as a cell-adhesion ligand in biomaterials for in vivo use is 
often questioned as it is known to have lower adhesion performance than several other 
proteins and protein fragments [194]. However, RGD is a ligand for αvβ3 integrin, 
known to be highly expressed in endothelial cells undergoing angiogenesis [195], and our 
preliminary results have demonstrated that RGD supports vessel invasion into degradable 
bio-artificial matrices. Therefore we argue that RGD is an acceptable ligand for 
vascularization studies while the PEG platform is amenable to experimentation with other 
types of adhesive molecules. Other adhesive ligands such as the collagen-mimetic peptide 
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GFOGER [196], the fibronectin fragment FNIII7-10 [194], and sequences from the ECM 
protein laminin can be used with the bio-artificial system for studying other types of 
regenerative applications such as neurite outgrowth, epithelial morphogenesis [131], and 
osteogenesis.  
While RGD seems an acceptable ligand to support vascular growth, the optimal 
adhesion molecule to support islet biology is more elusive. Basement membrane proteins 
are highly expressed in islets and it appears that most all cells types within the islet are 
capable of recognizing the RGD sequence. However, it remains to be seen whether RGD 
is a modulator of exocrine function or merely serves as a minimal adhesion molecule. 
Laminin is prevalent in the islet ECM in isoforms containing the familiar adhesive 
peptide sequences YIGSR, IKVAV, IKLLI, among others (reviewed in [197])  A 
majority of the beta-cells that produce insulin are buried within the islet interior and thus 
may have less contact with an exogenous encapsulating biomaterial than cells on the 
exterior of the islet. Therefore it is plausible that matrix-based signaling that affects beta 
cell function is translated through intercellular means to cells on the interior of the islet. 
Maintenance of islet basement membrane adhesion signals and rapid-reestablishment of a 
stable pro-vascular environment seem the most likely chance to mitigate the severe 
effects of isolating the islets from their native tissue environment. 
We emphasize that our strategy is not for synthetic bio-mimetic matrices to fully 
recapitulate the complete biological activities of native ECM. However, from an 
engineering perspective, bio-artificial matrices provide many advantages that make their 
use for regenerative therapeutics attractive. Most importantly, bio-artificial systems 
provide a high level of control to the designer using reproducible and synthetic 
components in modular “plug and play” architecture. A major conceptual aspect of these 
bio-artificial matrices is their application as engineered platforms for directed cell 
invasion: incorporating bioactive adhesion motifs and enzyme-specific cleavage sites 
rather than serving as simple polymeric growth-factor reservoirs.  
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CHAPTER 3 
BIO-FUNCTIONALIZED PEG-DIACRYLATE HYDROGEL TO 




Therapeutic vascularization remains a significant challenge in regenerative 
medicine applications. Whether the goal is to induce vascular growth in ischemic tissue 
or scale up tissue-engineered constructs, the ability to induce the growth of patent, stable 
vasculature is a critical obstacle. We engineered polyethylene glycol (PEG)-based bio-
artificial hydrogel matrices presenting protease-degradable sites, cell-adhesion motifs, 
and growth factors to induce the growth of vasculature in vivo. Compared to injection of 
soluble VEGF, these matrices delivered sustained in vivo levels of VEGF over two weeks 
as the matrix degraded. When implanted subcutaneously in rats, degradable constructs 
containing VEGF and RGD induced a significant number of vessels to grow into the 
implant at two weeks with increasing vessel density at four weeks. The mechanism of 
enhanced vascularization is likely cell-demanded proteolytic release of VEGF, as the 
hydrogels may degrade substantially within about two weeks through tissue remodeling. 
In a mouse model of hind limb ischemia, delivery of these matrices resulted in 
significantly increased rate of re-perfusion. These results support the application of 




                                                 
∗ adapted from: 
Phelps, E.A., et al., Bioartificial matrices for therapeutic vascularization. Proc. Natl. 
Acad. Sci. U.S.A. 2010 107(8):3323-8. 
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Introduction 
Reduced vascular perfusion represents a significant cause of death and 
hospitalization in the United States, including 8 million Americans with peripheral artery 
disease [198] and 16.8 million Americans with coronary heart disease [199]. Clinically 
viable therapeutic vascularization therapies will lead to better treatment for peripheral 
vascular disease, ischemic heart disease, and survival of cell and tissue transplants. 
Therapeutic vascularization has become a major research focus in regenerative medicine 
with several strategies being pursued [12, 200-206]. Most clinical trials have focused on 
delivery of a single angiogenic gene or growth factor, while several groups are 
developing strategies to deliver or activate different progenitor cell types. At present, a 
large focus of clinical and preclinical work is centered on identifying the ideal angiogenic 
agent (or combination therapy), delivery strategy, and dosing regimen [207]. There is a 
significant need for a suitable delivery vehicle to study novel vascular therapies in a 
controlled microenvironment. 
Hydrogel matrices enable a high level of control for delivering regenerative 
therapeutic treatments. While a large number of synthetic polymers have been shown to 
be useful implantable hydrogel materials [208, 209], polyethylene glycol diacrylate 
(PEG-DA) provides several advantages for regenerative therapeutics. PEG has a well-
established chemistry and long history of safety in vivo. Addition of acrylate groups 
flanking the PEG chain allows for photo- or chemical cross-linking of a PEG-DA 
macromer solution, as well as incorporation of biomolecules such as protease degradable 
sites, adhesive ligands, and growth factors. A major strength of this strategy is the 
modular “plug-and-play” design of the base hydrogel system that allows the tailoring of 
the biochemical and mechanical properties of the delivery vehicle. Due to its high water 
affinity, PEG is intrinsically resistant to protein adsorption and cell adhesion, providing 
extremely low background interference with incorporated biofunctionalities. Due to its 
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modular nature and excellent in vivo properties, PEG-DA is an appealing platform for 
delivering regenerative medicine therapies. 
PEG-DA-based bio-artificial matrices have been shown to promote cell survival 
and endothelial tube formation in vitro [108]. PEG vinyl-sulfone (PEG-4VS) matrices 
containing matrix metalloproteinase (MMP)-degradable, sites, adhesive ligands, and bone 
morphogenetic protein (BMP-2) promote bone formation in a cranial defect to similar 
extents as BMP-2-loaded collagen [210]. These bio-artificial matrices serve 
simultaneously as engineered delivery vehicles and temporary matrices to support tissue 
ingrowth and remodeling. The goal of this study was to further the use of modular PEG-
based matrices toward developing pro-vascularization therapies. We hypothesized that 
PEG-DA matrices containing a combination of protease degradable sites, adhesive 
ligands, and vascular endothelial growth factor (VEGF) would induce the growth of new 
vasculature into the implant in vivo and establish the therapeutic potential of this delivery 
vehicle in a model of hind limb ischemia. 
 
Results 
Regenerative biomaterials designed to integrate with the host tissue must provide 
mechanisms for cell invasion. We engineered bio-artificial hydrogel matrices to contain 
MMP-sensitive cross-links, adhesive ligands, and the growth factor VEGF (Fig. 3.2). 
MMP-degradable PEG-DA macromer (A-PEG-GPQ-PEG-A) was synthesized by 
reacting the proteolytically cleavable peptide GPQGIWGQK [210] with acrylate-
PEG3400-NHS, a primary amine reactive cross-linker. PEG-acrylate functionalized RGD 
adhesive ligand (A-PEG-RGD) was synthesized by reacting acrylate-PEG3400-NHS with 
the cell-adhesive peptide GRGDSPC. PEG-acrylate functionalized VEGF (A-PEG-
VEGF) was synthesized by reacting acrylate-PEG3400-maleimide, a sulfohydryl-reacting 
cross-linker, with VEGF121-cys, a growth factor containing an additional C-terminal 
cysteine [211]. A-PEG-VEGF activity was assessed by endothelial cell proliferation 
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assay and found to be equivalent to commercially available VEGF165. Hydrogel matrices 
consisting of A-PEG-GPQ-PEG-A, A-PEG-RGD, and A-PEG-VEGF, were generated by 
polymerizing the acrylate end-functional groups with low intensity UV light in the 
presence of the photoinitiator Ciba Irgacure 2959 (Fig. 3.2). Non-degradable matrices 
consisted of photopolymerized PEG-DA. 
Successful functionalization of bioactive ligands with acrylate-PEG-NHS was 
confirmed by demonstrating increased molecular weight distributions (Fig. 3.1). Cells 
express MMPs as they invade tissue and biological matrices such as collagen. The 
degradation profile of the bio-artificial matrix is an important aspect as it is designed to 
maintain structural integrity in vivo and only degrade subsequent to tissue invasion. 
Susceptibility of A-PEG-GPQ-PEG-A hydrogels to MMP-mediated degradation was 
confirmed by progressive dissolution during incubation with active MMP-2 enzyme or 
collagenase-I over 20 hours (Fig. 3.3). Gel degradation was slowed by addition of the 
MMP-2 inhibitor oleoyl-N-hydroxylamide. Untreated gels with MMP-degradable 
sequences swelled slightly over 20 hours with no weight loss and remained intact for 4 
weeks in PBS. These results demonstrate that controlled degradation of synthetic 
hydrogels can be achieved by incorporating MMP-sensitive cross-links. 
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Figure 3.1 PEG-acrylate modification of bioactive ligands prior to gel formation. 
(A) MMP-degradable peptide cross-linker is functionalized with two molecules of A-
PEG-NHS to make a bi-PEG-acrylated flanked degradable sequence. Adhesive ligands 
and growth factors are mono-PEG-acrylated. (B) Biomolecules functionalized with PEG-
acrylate have increased molecular weight when run on an SDS-PAGE gel. (i) Fluorescent 
imaging - Lane 1: RGD-FITC, Lane 2: A-PEG-RGD-FITC. (ii) BaCl2 / Iodine stain: 





Figure 3.2 PEG-DA hydrogel formation schematic. (A) An aqueous solution of 
PEGylated precursors is exposure to UV light in the presence of photoinitiator 
compounds. (B) Polymerization of acrylate end groups into polyacrylic acid results in a 
cross-linked hydrogel (C) Macroscopic view of a PEG-DA hydrogel cast in an 8 mm x 2 





Figure 3.3 In vitro results for PEG-DA hydrogel degradation and encapsulated cell 
spreading. (A) Degradation of bio-artificial hydrogels incubated in collagenase-1 or 
MMP-2. Gels are seen to degrade after several hours of incubation, while degradation is 
decreased by addition of inhibitor and gels in PBS do not degrade. (B) Calcein viability 
stain of NIH-3T3 fibroblasts seeded in hydrogel formulations spread and migrate in  bio-
artificial matrices with degradable sequences and adhesive sites (i) similar to type I 
collagen (iv) but remain rounded in non-degradable (ii) or non-adhesive (iii) matrices.  
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In order to assess the functionality of the adhesive and degradation components of 
3D hydrogels prior to implantation, NIH3T3 fibroblasts were encapsulated in gel 
formulations containing MMP-degradable sites, RGD, neither, or both. Cells remained 
rounded in gels containing only RGD or MMP-degradable sites but exhibited a spread 
morphology in gels containing both RGD and MMP-degradable sites, similar to cells in 
type I collagen (Fig. 3.3). These results indicate that both adhesive ligands and MMP-
degradable sites are necessary for cells to spread within the bio-artificial 3D environment 
and are in agreement with published in vitro studies [212]. The intrinsically low 
background signal of PEG permits detection of sensitive engineered biofunctional effects, 
and subsequent focused manipulation of these effects. 
VEGF release from the hydrogel was measured in vivo by labeling A-PEG-VEGF 
with the amine-reactive infrared dye ICG-sulfo-OSu. ICG was observed to have 
significantly higher fluorescence after exposure to UV-photocross-linking compared to 
other dyes tested. Pre-formed constructs consisting of 10% PEG-DA or A-PEG-GPQ-
PEG-A and 2.8 µmol/mL A-PEG-RGD + 80 µg/mL A-PEG-VEGF-ICG were implanted 
subcutaneously in male Lewis rats. Control rats received subcutaneous injections of A-
PEG-VEGF-ICG in PBS or matrices with no VEGF. The fluorescent signal in the rats 
was measured on a Caliper Xenogen IVIS Lumina bioluminescent imaging system at 0, 
1, 3, 7, and 14 days post implantation. The fluorescent signal in the implant was 
quantified by gating a region of interest (ROI) around the periphery of the implant and 
subtracting the average background counts in the surrounding tissue from the average 
total counts in the implant, as background intensity varied between animals. A steady 
decline in signal intensity for the soluble VEGF injection was observed, with 90% of the 
signal lost by two weeks of implantation (Fig 3.4). In contrast, the degradable hydrogel 
matrix exhibited constant VEGF levels during the first two days followed by a gradual 
decrease over the next 12 days. The non-degradable matrix with VEGF showed nearly 
constant levels of VEGF over the two week implantation period. The soluble VEGF 
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group had much higher initial fluorescence because this group was not exposed to UV 
light. We found that ICG exposure to UV light without the addition of PEG chains to 
absorb photoinitiator-generated radicals resulted in elimination of any detectable ICG 
signal. Samples containing un-labeled VEGF were undistinguishable from background 
fluorescence. Upon retrieval of the implants at day 14, the degradable samples were seen 
to have partially degenerated, and in some animals the gel was entirely dissociated. The 
non-degradable samples remained completely intact. New vessels were seen to grow in 
the tissue surrounding the implants with a general trend of a higher density of small blood 
vessels in tissue immediately adjacent to the implant. Larger and more regular vessels 
were seen growing into and around degradable implants, while non-degradable implants 
induced a large number of small vessels in the surrounding tissue. 
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Figure 3.4 Degradation of subcutaneous implants containing ICG-labeled VEGF. (A) 
Quantification of VEGF fluorescent signal in implants shows early release for degradable 
matrix and late release for non-degradable matrix. Soluble injection shows continuous 
decline in signal strength. N=10 (B) Representative images from IVIS scanning of 
fluorescently labeled VEGF in degradable implants, non-degradable implants, and PBS 
injection. Number indicates average counts per unit area within ROI.  
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We next evaluated the ability of these bio-artificial matrices to promote 
vascularization in a subcutaneous implantation site. Hydrogels were photopolymerized in 
cylindrical silicone molds (9mm dia, 2mm thick) around poly-caprolactone (PCL) mesh 
disks to allow for visualization and retrieval of implants. Gel formulations included 
unfunctionalized PEG-DA, MMP-degradable, MMP-degradable + RGD, or MMP-
degradable + RGD + VEGF. The gel concentrations of 10% (w/v) PEG-DA or A-PEG-
GPQ-PEG-A [213], 2.8 µmol/mL A-PEG-RGD [214], and 80 µg/mL A-PEG-VEGF 
[211] were used. Hydrogel constructs were implanted dorsally in male Lewis rats. At 2 or 
4 weeks, subjects were perfused with a radio-opaque silicon-based vascular contrast 
agent to gather quantitative and 3D structural data on patent blood vessel ingrowth [215]. 
Examination of explanted constructs revealed that hydrogels remained intact except for 
degradation by invading blood vessels, even after 4 weeks in vivo. Micro-CT analysis of 
the scanned constructs was gated within the periphery of the PCL ring to ensure only 
vessels inside the hydrogel were measured (Fig. 3.5). Evaluation of the scanned explants 
revealed approximately 6-fold increased vascular density at 2 weeks and 12-fold 
increased vascular density at 4 weeks for degradable gels containing adhesive ligands, 
degradable sites, and VEGF compared to all other groups. The patency of the neo-
vasculature was shown to be connected to the host circulatory system because contrast 
agent perfused through the aorta reached the vessels in the implant. These results validate 
the in vivo vascularization potential of the engineered hydrogel constructs. 




Figure 3.5 MicroCT tomograms of bio-artificial matrices implanted subcutaneously in 
rats perfused with Microfil radio-opaque contrast agent. (A,B) At 2 and 4 weeks, GPQ + 
RGD + VEGF implants showing vasculature in surrounding tissue growing into implant, 
grey area defines extent of implant. (C) Representative scans from non-degradable 
implants with no adhesive ligands (PEG-DA), non-degradable with adhesive ligands 
(PEG-DA + RGD), degradable with no adhesive ligands (GPQ), degradable with 
adhesive ligands (GPQ + RGD), and degradable with adhesive ligands and bound VEGF 




Depending on the therapeutic application, bio-artificial matrices can be delivered 
as pre-formed constructs containing cells and other regenerative agents such as growth 
factors, or can be delivered as macromer solutions and polymerized in situ. To test the 
ability of PEG-based bioartificial matrices to improve reperfusion rates in a model of 
peripheral limb ischemia, we chose to deliver the matrix as a macromer solution and 
polymerize it in situ. By delivering the matrix as a macromer solution followed by in situ 
polymerization, we integrated the matrix more deeply within the target tissue than 
application of a pre-formed construct would have allowed. Macromer solutions of the 
PEG-DA-based bio-artificial matrix components were formulated to include RGD and 
MMP-degradable sites, with or without the addition of VEGF. Our preliminary studies 
indicated that better cell invasion and tissue integration occurs at lower concentrations of 
PEG hydrogel. We therefore reduced the concentration of A-PEG-GPQ-PEG-A to 5% 
(w/v) for this study, but kept the concentrations of A-PEG-RGD and A-PEG-VEGF at 
2.8 µmol/mL and 80 µg/mL, respectively. The left leg femoral artery of 8-9 week old 129 
mice was ligated and excised in compliance with a well-established model of peripheral 
limb ischemia [159, 160, 216, 217]. The right leg was left undisturbed to serve as a 
control reference. During femoral artery excision surgery, mice received (i) no treatment, 
or injections of (ii) PBS (vehicle control), (iii) soluble A-PEG-VEGF, (iv) soluble 
hydrogel precursors, or (v) soluble hydrogel precursors with A-PEG-VEGF at 3 sites (50 
µL each) in the muscle groups surrounding the femoral artery region. Injected precursor 
solutions were immediately polymerized with low-intensity UV light exposure. The 
precursor solution injected into the muscle was seen to fully polymerize in situ during 
necropsy of test mice, indicating that the UV light penetrated the tissue deeply enough to 
cross-link the precursor solution. Preliminary studies established that exposure to the 
same UV wavelength, intensity, and duration on skin, muscle, or small bowel mesentery 
resulted in no detectable inflammation, tissue damage, or increased angiogenesis. At 4 
and 7 days post-surgery, mice were imaged on a Laser Doppler Perfusion Imaging 
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(LDPI) system to quantitatively analyze perfusion to the peripheral limb. The perfusion 
ratio of the ischemic limb compared to the non-ischemic limb in each animal was taken 
as the measurement for comparison in both the foot and the leg (ankle to proximal 
ligation) (Fig. 3.6). At day 4, the mice receiving matrix with VEGF showed a trend of 
increased perfusion in the leg although the differences were not statistically significant 
(p=0.056), and no trend was seen in the feet, although the PBS control group is slightly 
elevated. By day 7, animals receiving hydrogels with VEGF exhibited a 50% increase in 




Figure 3.6 Hind limb perfusion in mice with ligated femoral artery. (A) LDPI imaging of 
limb  perfusion at day 7 responding to treatment conditions: no treatment, PBS injection, 
soluble A-PEG-VEGF121-cys injection, degradable matrix with adhesive ligands (GPQ 
+ RGD), and degradable with adhesive ligands and bound VEGF (GPQ + RGD + 
VEGF). (B) Quantification of perfusion ratio (normal leg : ischemic leg) at days 4 and 7 




Pro-vascularization therapy remains a significant challenge in regenerative 
medicine. We adapted the PEG-DA platform for in vivo vascularization applications and 
demonstrated efficacy with both construct implantation and in situ polymerization in 
subcutaneous and ischemia models. We first demonstrated ability to generate the 
PEGylated matrix components and form a hydrogel construct by UV 
photopolymerization. We showed that the hydrogels degrade in the presence of enzymes 
typically expressed by invading cells but not in buffer solution. We also showed that cells 
in the matrix require both adhesive sequences and degradable sites in order to spread 
within the bio-artificial gel. This result indicates that the bio-artificial material is a 
suitable matrix to promote tissue ingrowth and remodeling. 
We showed that incorporation of VEGF in engineered hydrogel matrices 
modulated in vivo release kinetics. In gels containing proteolytically degradable cross-
links, the matrix is designed to only release VEGF as the matrix is digested by invading 
cells. Degradable hydrogel matrices exhibited constant VEGF levels during the first two 
days followed by a gradual decrease over the next 12 days, whereas non-degradable 
matrices with VEGF showed nearly constant levels of VEGF over the two week 
implantation period. These results indicate that incorporation of degradable cross-links in 
the hydrogel controlled the release of VEGF from the matrix. In contrast, injected soluble 
VEGF levels steady declined with 90% of the signal lost by two weeks of implantation as 
expected for diffusion and turnover.  
We next tested the ability of pre-cast constructs to vascularize in a rat 
subcutaneous implant model. Engineered hydrogels containing MMP cleavage sites, 
RGD, and bound VEGF significantly enhanced vessel ingrowth by 2 weeks with 
increasing vasculature at 4 weeks. Importantly, the patency of this observed vascular 
ingrowth at 4 weeks was preserved, as shown by the ability of contrast agent perfused 
through the aorta to reach vessels within the implant. Matrices lacking either VEGF or 
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RGD showed minimal tissue invasion. Non-degradable matrices failed to integrate with 
the host tissue on any level. We attribute the presence of long-term patent vessels at 2 and 
4 weeks to controlled VEGF release and bioavailability from the degradable hydrogel.  
The subcutaneous implantation experiment used 10% (w/v) hydrogels, consistent with 
the polymer density used in published reports [210, 212, 213]. While conducting 
preliminary research for another in vivo study, we discovered that lower density 
hydrogels are potentially more useful for vascularization purposes as vessel invasion is 
faster and of higher density in more-easily degradable gels. Many researchers are 
interested in vascular-inductive matrices for cell-transplant applications, in which case 
vessel ingrowth will need to occur within a matter of days and not weeks to avoid 
ischemic-related die-off of transplanted cells. Future studies with bio-artificial matrices 
for construct implantation should examine ways to improve vessel density and ingrowth-
rate, one method being through reducing the amount of material that needs to be 
degraded for cell invasion. 
Lastly, we implemented in situ polymerization of the bio-artificial matrix in a 
mouse hind-limb ischemia functional model. Macromer solutions of matrix and matrix + 
VEGF injected into the muscle in areas made ischemic by femoral artery ligation were 
polymerized in situ with UV light. Blood perfusion to the ischemic limb was measured 
by LDPI and found to be greatest in animals that received matrices with bound VEGF at 
day 7 post-surgery. The result that the engineered matrix containing VEGF performs 
better than injection of soluble VEGF is noteworthy because it indicates that the delivery 
vehicle is acting synergistically to amplify the effect of the growth factor. It is presumed 
that the increased perfusion is due to growth factor sequestration in the matrix, resulting 
in prolonged exposure that persists as the matrix is degraded and remodeled, as shown 
with sustained release in the in vivo degradation experiment. Furthermore, the adhesive 
ligands and degradable sequences in the matrix are designed to interact with endothelial 
cells undergoing angiogenesis. In reperfusion to the leg, the matrix alone (no VEGF) 
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performed as well as soluble VEGF injection, indicating that the engineered adhesive and 
degradable hydrogel matrix itself has a beneficial healing or supportive effect. These 
results demonstrate the effective use a bio-artificial hydrogel to act synergistically as a 
directive scaffold and a growth factor delivery vehicle. 
Several noteworthy studies indicate that delivery of VEGF has limited therapeutic 
success at achieving long-term, stable, vascular growth in humans [200]. While a strong 
stimulator of vascular growth, VEGF administration alone has limited ability to induce 
the growth of larger vessels. Long-duration exposure is necessary to produce stable 
microvasculature that does not regress after withdrawal of the VEGF stimulus [218, 219]. 
In this study, we achieved steady vascular ingrowth continuing to a mid-range time point 
of 4-weeks when the study was terminated. Based on the VEGF release results, we 
attribute the persistent vascularization to the conjugation of VEGF to the matrix, where it 
is only released in a proteolytically-dependent manner as opposed to diffuse or bolus 
injection delivery methods. This result is consistent with other reports that have used 
sustained-release strategies [99, 211, 220]. By binding the growth factor to the matrix, a 
persistent pro-vascularization signal is generated that does not quickly ramp up and fade 
away as in a soluble delivery method. The modular nature of bio-artificial matrices makes 
studying the effects of other pro-vascularization factors in the same controlled 
environment extremely straightforward. Future studies incorporating more or different 
factors may be able to achieve even more robust healing effects. 
The use of RGD as an adhesive ligand is often disputed as it is known to have 
lower adhesion performance than several other proteins and protein fragments [194]. 
However, RGD is a ligand for αvβ3 integrin, known to be highly expressed in endothelial 
cells undergoing angiogenesis [195], and our results have demonstrated that RGD 
supports vessel invasion into degradable bio-artificial matrices. The PEGDA platform is 
amenable to experimentation with other types of adhesive molecules. For example, 
ephrin was demonstrated to support endothelial cell adhesion and tubulogenesis [213]. 
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Other adhesive ligands such as the collagen-mimetic peptide GFOGER [196], the 
fibronectin fragment FNIII7-10 [194], and sequences from the ECM protein laminin can 
be used with the bio-artificial system for studying other types of regenerative applications 
such as neurite outgrowth, epithelial morphogenesis [131], and osteogenesis. 
 
Conclusion 
We emphasize that our strategy is not for synthetic bio-mimetic matrices to fully 
recapitulate the complete biological activities of native ECM. However, from an 
engineering perspective, bio-artificial matrices provide many advantages that make their 
use for regenerative therapeutics attractive. Most importantly, bio-artificial systems 
provide a high level of control to the designer using reproducible and synthetic 
components in modular “plug and play” architecture. A major conceptual aspect of these 
bio-artificial matrices is their application as engineered platforms for directed cell 
invasion: incorporating bioactive adhesion motifs and enzyme-specific cleavage sites 
rather than serving as simple polymeric growth-factor reservoirs. In the implantation 
studies it appears that the matrix does not remain long term and is fully degraded over a 
period of weeks as new tissue forms. Based on this observation, the dominant mechanism 
of vascularization is likely cell-demanded / proteolysis-dependent release of VEGF.  
Further studies into the growth factor release kinetics in vivo and cellular activity at the 
tissue-hydrogel interface are warranted to better characterize the specific nature of the 
observed therapeutic effects. 
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Materials and Methods 
 
Matrix synthesis and degradation profile 
Peptides were custom prepared by a commercial manufacturer (AAPPTEC) and 
supplied at 95% purity. Two molar equivalents of A-PEG-SCM (Creative PEGworks) per 
mole of GPQGIWGQK were dissolved in toluene and evaporated to a thick oil; the molar 
ratio of A-PEG-SCM to GRGDSPC and GGRGDSPGGK-carboxyfluorescein (RGD-
FITC) was 1:3. The evaporated oil was dissolved in DMF to bring the concentration of 
A-PEG-SCM to 50 mg/mL. The peptides to be PEGylated were added along with one 
molar equivalent of TEA per mole of A-PEG-SCM and reacted for 4 hours. The product 
was precipitated in ether and dried, then dissolved in diH2O, sterile filtered, and purified 
by dialysis. Products were lyophilized and stored at -20°C. PEGylated products were run 
on a 20% SDS-PAGE gel to check for molecular weight increase. A-PEG-RGD-FITC 
was visualized directly by fluorescence to confirm small peptide PEGylation. A-PEG-
GPQ-PEG-A was visualized by barium chloride / iodine stain described in [221]. Gels 
were degraded in vitro with 20 mU/mL collagenase-I (Sigma), 200 pM MMP-2 
(Calbiochem), or 200 pM MMP-2 + 40 µM oleoyl-N-hydroxylamide (Calbiochem). 
Weight loss was determined by wet weight percent change.  
 
VEGF synthesis 
BL21 Star(DE3) E. coli (Invitrogen) were transformed with VEGF121-cys plasmid 
prepped from DH5α E. coli (Invitrogen) following manufacturer’s instructions. 
Transformed BL21 Star(DE3) cells were induced with 1mM IPTG at OD600=0.8. After 4 
hours, cells were pelleted and frozen at -20°C. Pelleted cells were thawed and lysed in B-
PER protein extraction reagent (Pierce). Inclusion bodies containing VEGF121-cys were 
separated from soluble protein by centrifugation at 15,000xg and were solubilized for 1 
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hour on ice in 10 mL B-PER reagent + 6M urea. VEGF121-cys was purified by 6X His-
Bind column (Pierce) following manufacturer’s instructions with addition of 6M urea to 
wash and elution buffers. 2mM DTT was added to the elution fraction which was 
sequentially dialyzed for 24 hours against 4M urea, 1mM EDTA, 150mM NaCl, 25mM 
Tris-HCl, pH 7.5, followed by dialysis against 2M urea, 1mM EDTA, 150mM NaCl, 
25mM Tris-HCl, pH 7.5, and dialysis against 1X PBS. Endotoxin was removed from 
protein solution by a Detoxi-Gel Endotoxin Removing Column (Pierce) and endotoxin 
levels were verified to be below 0.1 EU/mL by Limulus Amebocyte Lysate colorimetric 
assay (Lonza). Protein was concentrated to 1 mg/mL and stored at -80°C in 50% 
glycerol. VEGF121-cys purity was verified by SDS-PAGE with Coomassie staining / 
Western blot and specificity by ELISA detection. VEGF121-cys was functionalized by 
incubation overnight at 4°C with 50 molar excess acrylate-PEG-maleimide (Laysan Bio, 
custom order) in PBS. Functionalization was verified by molecular weight increase seen 
by SDS-PAGE and Coomassie staining. A-PEG-VEGF121-cys activity was verified by 
addition to endothelial basal media (MCDB-121, 5% FBS, + ascorbate, L-glutamine) at 
concentration intervals and observing the effect on endothelial cell proliferation as 
compared to VEGF165 (Invitrogen). 
 
3D construct cell seeding 
A-PEG-GPQ-PEG-A was dissolved in PBS at 10% (w/v) with 0.05% Irgacure 
2959 (Ciba) photoinitiator. NIH3T3 cells were added at 300,000 cells/mL. 9 mm x 1 mm 
silicone isolator wells (Grace Bio Labs) were adhered to glass slides and filled with 70 
µL PEGDA solution per well. Macromer solutions were cross-linked by exposure to 365 
nm UV light at 10 mW/cm2 for 12 min and placed in 1 mL of DMEM + 10% FBS and 
incubated for 24 hours. Cells in 3D culture were stained with calcein AM for imaging and 




In vivo degradation study 
A-PEG-VEGF121-cys was labeled by overnight incubation at 4°C with 200 molar 
excess of the dye ICG-sulfo-OSu (Dojindo). Excess dye was removed by two rounds of 
gel filtration through Zeba Spin desalting columns (Pierce). 150 µL constructs consisting 
of 10% (w/v) A-PEG-GPQ-PEG-A, 2.8 µmol/mL A-PEG-RGD, 80 µg/mL ICG-VEGF 
with 0.05% Irgacure 2959 in PBS were cast in 9 mm x 2 mm molds and polymerized 
with a 10 min exposure to UV light. Constructs consisting of 10% PEG-DA + RGD + 
ICG-VEGF were used as non-degradable controls, while constructs with unlabeled A-
PEG-VEGF121 were used as imaging controls. Implants were equilibrated in PBS for 24 
hours to leach out any unbound ligand. Five rats per condition each received 2 dorsal 
subcutaneous implants or 150 µL subcutaneous injections of soluble ICG-VEGF. Rats 
were imaged at 745 nm excitation, 840 nm emission, and 60 s exposure time in a 700 
series Xenogen IVIS machine. Images were analyzed for background-subtracted average 
photon counts within an ROI gated over the implant site.  
 
Subcutaneous vascularization, microfil perfusion, and microCT imaging 
Rings of 2 mm thickness PCL mesh (66% porosity, 300-500 um pore size) were 
made with concentric 8 mm and 5 mm sterile biopsy punches. The macroporous nature of 
these meshes readily allows tissue and vascular ingrowth. 100 µL constructs consisting of 
10% (w/v) A-PEG-GPQ-PEG-A, 2.8 µmol/mL A-PEG-RGD, 80 µg/mL A-PEG-VEGF 
with 0.05% Irgacure 2959 in PBS were cast in 9 mm x 2 mm molds containing the PCL 
rings. Implants were equilibrated in PBS for 24 hours. 16 male Lewis rats each received 4 
randomized dorsal subcutaneous implants. After sacrifice by CO2 inhalation, rats were 
perfused with 0.9% saline + 4 mg/mL papaverine hydrocholoride (Sigma), followed by 
0.9% saline, and 10% neutral buffered formalin. After fixation, 30 mL of 80% (v/v) 
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diluted MV-122 Microfil (Flowtec) was injected into the aorta with a syringe and allowed 
to polymerize overnight before implant retrieval. Explants were scanned at 16 µm 
resolution with a Scanco μCT-40 microCT machine. ROI’s were gated inside the edge of 
the PCL rings.  
 
Hind limb ischemia and LDPI imaging 
At eight to nine weeks of age, male 129 mice (Charles River) were anesthetized 
with intraperitoneal injections of xylazine (10 mg/kg) and ketamine (80 mg/kg). A 
unilateral incision was made over the left medial thigh of the mouse. The superficial 
femoral artery and vein were ligated proximal to the caudally branching deep femoral 
artery and proximal to the branching of the tibial arteries. The portion of the artery and 
vein between the ligation points was excised. One hundred and fifty microliters of PBS, 
A-PEG-VEGF suspended in PBS, or non-polymerized A-PEG-GPQ-PEG-A (5% w/v) + 
A-PEG-RGD (2.8 µmol/mL) (with or without 80 µg/mL A-PEG-VEGF) + 0.05% 
Irgacure 2959 were injected into 3 sites in the ischemic muscle. The muscle was then 
exposed to 15 minutes of UV light (365 nm, 10 mW/cm2), which induced polymerization 
of the matrix. As an additional control, no solution was injected to the muscle and the 
mice were not exposed to UV light. The skin was closed with interrupted silk sutures. 
LDPI ( Moor Instruments) was used to evaluate the perfusion in the ischemic and non-
ischemic legs at 4ms/pixel scan speed, 256 x 256 resolution in arbitrary perfusion units. 
Perfusion was estimated (1) in the feet and (2) in the ischemic portion of the legs not 
including the feet. The non-ischemic legs and feet were used as controls. The results were 
reported as ratios of surgery to non-surgery leg/foot for each animal to account for natural 







Statistical analyses were performed using one-way ANOVA with Tukey’s test for 
post-hoc comparisons. For LDPI analysis, the perfusion values for the contra-lateral non-
operated leg were used as covariants. A p-value of 0.05 was considered significant. 
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CHAPTER 4 
ENGINEERING OF BIO-FUNCTIONALIZED PEG-MALEIMIDE 




We developed an improved polyethylene glycol bioartificial matrix for 
regenerative medicine by utilizing maleimide cross-linking chemistry. This hydrogel 
chemistry is advantageous for cell delivery due to the mild cross-linking reaction that 
occurs rapidly enough for in situ delivery, while easily lending itself to “plug-and-play” 
design variations such as incorporation of enzyme-cleavable cross-links and cell-
adhesion peptides. We have shown improved reaction efficiency, wider range of Young’s 
moduli and polyer weight percentage gels, faster gelation, and applicability for in situ 
delivery. These numerous advantages place the maleimide crosslinked gels ahead of other 
Michael-addition crosslinker and polyethylene glycol diacrylate for our application of in 
vivo delivery of angiogenic therapeutics and islet cell transplantation. 
 
Introduction 
Hydrogels, highly hydrated cross-linked polymer networks, have emerged as 
powerful synthetic analogs of extracellular matrices for basic cell studies as well as 
promising biomaterials for regenerative medicine applications.[209] A critical advantage 
of these artificial matrices over natural networks is that bioactive functionalities, such as 
cell adhesive sequences and growth factors, can be incorporated in precise densities while 
                                                 
 
∗ adapted from: 
Phelps, E.A., et al. Maleimide cross-linked bioactive PEG hydrogel exhibits improved 
reaction kinetics and cross-linking for cell encapsulation and in-situ delivery. Advanced 
Materials, under review. 2011. 
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the substrate mechanical properties are independently controlled.[222-227] Polyethylene 
glycol (PEG) hydrogels represent the ‘gold standard’ in this field due to their intrinsic 
low-protein adsorption properties, minimal inflammatory profile and history of safe in 
vivo use, ease in incorporating various functionalities, and commercial availability of 
reagents. In the present study, we explored the use of an alternative reactive cross-linking 
moiety for PEG hydrogels, the maleimide functional group. We demonstrate several 
advantages over other cross-linking chemistries, namely stoichiometric hydrogels with 
improved cross-linking efficiency, bioligand incorporation and reaction time scales 
appropriate for clinical use for in situ gelation. The maleimide reactive group is 
extensively used in peptide bioconjugate chemistry because of its fast reaction kinetics 
and high specificity for thiols at physiological pH.[228] For these experiments, we used a 
4-arm PEG-maleimide (PEG-4MAL) macromer and compared it to 4-arm PEG-acrylate 
(PEG-4A), 4-arm PEG-vinylsulfone (PEG-4VS), and UV photo-cross-linked PEG-DA.  
Various cross-linking chemistries have been described to create bioactive 
hydrogel networks of PEG macromers, with Michael-type addition reactions and acrylate 
polymerization being the most widely utilized.[224] Cross-linking chemistry, gelation 
time, polymer network structure, and buffer conditions are important considerations when 
selecting a hydrogel cross-linking format for basic cell biology studies or regenerative 
medicine applications. In PEG-diacrylate (PEG-DA) hydrogels, PEG-DA macromers are 
cross-linked via free-radical initiated polymerization of acrylate end groups. Free radicals 
are created either by chemical activation or UV cleavage of a photoinitiator with the 
added ability to spatially control the presentation of incorporated ligands or mechanical 
properties through additive [229, 230] or subtractive [231] photo-patterning. A major 
drawback of free-radical cross-linking is that it can significantly reduce encapsulated cell 
viability and is unwieldy for in vivo delivery of hydrogels cross-linked in situ. In contrast, 
for hydrogels cross-linked by Michael-type addition, functionalized end groups on 
branched PEG macromers are reacted with bi-functional or branched cross-linking 
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molecules. Michael-addition PEG hydrogels based on 4- or 8-arm PEG macromers with 
acrylate [98, 232, 233], vinyl-sulfone [234-238], and thiol [239-243] end-groups have 
been extensively investigated. Michael-type addition cross-linking avoids the use of 
cytotoxic free-radicals and UV light, but instead require a nucleophilic buffering reagent 
[244], such as triethanolamine (TEA) or HEPES [245], to facilitate the addition reaction. 
However, hydrogels formed in the presence of high concentrations of TEA have 
cytotoxic effects on sensitive cell types such as endothelial cells, and cells in ovarian 





Figure 4.1 PEG-maleimide hydrogel chemistry (A) Maleimide Michael-type addition 
reaction. (B) 4-arm PEG Maleimide macromer. (C) Acrylate and vinyl sulfone reactive 
groups. (D) Sample cross-linked PEG-4MAL hydrogel. E) Michael-type addition 
hydrogel reaction scheme: PEG-macromers are first functionalized with RGD adhesive 





Figure 4.2 PEG-4MAL reacted with GRGSPC-Fluorescein at increasing PEG-4MAL to 
RGD molar ratios. (A) Increased molecular weight seen by SDS-PAGE indicates RGD 
conjugated to 4-arm PEG. (B) Lower MAL:RGD molar ratios with excess RGD (ex: 1:1) 
result in multiple RGD conjugations per 4-arm PEG compared to reactions with excess 




PEG-DA, PEG-4MAL, and PEG-4A macromers (20 kDa, >95% end-group 
substitution) were obtained from Laysan Bio. PEG-4VS (20 kDa) was synthesized as 
previously reported.[131] Michael-type addition hydrogels incorporating cell adhesive 
ligands were formed in two steps. First, end-functionalized 20 kDa four-arm PEG 
macromers (PEG-4A, PEG-4MAL, PEG-4VS) were reacted with a thiol-containing 
adhesive peptide GRGDSPC in PBS with 4 mM or 400 mM TEA at pH 7.4 for 1 hour 
(Fig. 4.1). Physical conjugation of the peptide to PEG-macromer was confirmed by 
increased molecular weight of fluorescein-labeled RGD visualized by SDS-PAGE (Fig. 
4.2). RGD-functionalized PEG macromers were subsequently cross-linked into a 
hydrogel by addition of the dithiol protease-cleavable peptide cross-linker 
GCRDVPMSMRGGDRCG[247, 248] at a 1:1 molar ratio of remaining PEG reactive end 
groups to peptide thiols. The protease-cleavable peptide cross-linker is necessary for cell 
encapsulation studies (see below).[131, 249] It has been reported that RGD 
concentrations ranging between 25 µM and 3.5 mM support 3D cell adhesion and 
spreading in PEG hydrogels.[125, 212, 213, 247, 250-252] We used an RGD 
concentration of 2.0 mM to maximize adhesion sites while retaining cross-linking ability 
in tetra-functionalized PEG macromers. To determine the incorporation efficiency of 
RGD peptide and the conjugation efficiency of the different Michael-addition reagents, 
we measured unreacted/free thiols in the reaction buffer over time with the Measure-iT 
thiol quantification kit (Invitrogen). We observed rapid reaction of RGD with PEG-
4MAL and nearly 100% incorporation at MAL:RGD molar ratios 1:1 and higher in both 
4 mM and 400 mM TEA as early as 10 min (Fig. 4.3A). Both PEG-4VS and PEG-4A 
exhibited poor RGD incorporation in 4 mM TEA. At 400 mM TEA, PEG-4VS showed 
complete RGD incorporation only at VS:peptide molar ratios 4:1 and higher and after 60 
min incubation, whereas PEG-4A required a A:peptide molar ratio of 8:1 for complete 
RGD incorporation at 60 min. For all 4-arm PEG hydrogels incorporating 2.0 mM RGD, 
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the reactive group to RGD molar ratio was 2.73:1 or greater. PEG-DA functionalization 
with RGD required a separate 1 hour reaction with acrylate-PEG-NHS with excess RGD 
peptide followed by purification and concentration of the product. 
The lower reaction efficiency of PEG-4VS and PEG-4A macromers is also 
reflected in the inability to form low weight percentage gels. Whereas PEG-4MAL forms 
gels as low as 3%, we observed lower polymer weight percentage limits of 7.5% for 
PEG-4A, 4% for PEG-4VS, and 7.5% for PEG-DA. Additionally, the time to gelation 
was significantly shorter in PEG-4MAL (~1-5 min) in 4 mM TEA compared to PEG-
4VS (~ 30-60 min) or PEG-4A (˃ 60 min) in 400 mM TEA and 10 minutes for PEG-DA 
under 10 mW/cm2 365 nm UV light. Fast gelation times are critically important for 
uniform distribution of encapsulated cells in 3D cultures and allow for in situ gelation of 
conformal gels in regenerative medicine applications. For the remaining studies, PEG-
4MAL gels were formed in 4 mM TEA while PEG-4VS and PEG-4A were formed in 
400 mM TEA. 
Hydrogel swelling ratio is related to the average distance between cross-links by 
the modified Flory-Rehner equations as described by Peppas [253, 254] and is an 
indication of overall hydrogel network structure [192, 226, 235, 236, 255]. A higher mass 
swelling ratio indicates a more loosely cross-linked network. We measured the 
equilibrium mass swelling ratio for PEG-4MAL, PEG-4VS, PEG-4A, and PEG-DA gels 
containing 2.0 mM RGD at multiple polymer weight percentages (wt/v) (Fig. 4.3B). For 
PEG-4MAL hydrogels, the equilibrium mass swelling ratio (Qm) was greater than 500 for 
3.0% gels indicating a very loose network. Qm was dramatically lower in 4.0% PEG-
4MAL gels (~150) with swelling decreasing only moderately in higher percent gels. For 
both PEG-4A and PEG-4VS gels, the swelling ratio was higher compared to PEG-4MAL 
and decreased as polymer weight percentage increased from 7.5% to 10.0%. PEG-4A 
swelling remained 2 -3 fold higher than PEG-4MAL swelling between 7.5% and 10%. 
PEG-4VS swelling was 2-fold higher than PEG-4MAL swelling at 7.5% but the swelling 
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ratio was identical at 10.0%. The PEG-4MAL swelling curve features an inflection that 
suggests a transition from a non-ideal, high-swelling network at 3.0% to a more robust, 
moderate-swelling network (Qm <200) at polymer weight percentage greater than or 
equal to 4.0%. In contrast, PEG-4VS network swelling ratio remains above this threshold 
until the polymer weight percentage exceeds 7.5%. PEG-4A gels remain in a high-
swelling regime even at 10%. PEG-DA had a low mass swelling ratio for all polymer 
weight percentages. This low-swelling ratio results from the acrylate polymerization 
cross-linking reaction which generates in a highly entangled and cross-linked network 
structure. These mass swelling ratio measurements suggest that PEG-4MAL gels offer 
superior network-forming characteristics compared to PEG-4VS and PEG-4A. The very 
low mass swelling ratio of the PEG-DA gel suggests that degradation by host-tissue or 
encapsulated cells would be more difficult due to denser bulk properties. 
We next measured hydrogel Young’s modulus using atomic force microscopy 
indentation testing. PEG hydrogel samples with 2 mM RGD were prepared and allowed 
to swell overnight in H2O prior to mechanical testing. Measurements for hydrogels below 
10% (wt/v) for PEG-DA, PEG-4A, and PEG-4VS or below 4% (wt/v) PEG-4MAL were 
not obtained as the material was too viscous for the AFM probe to accurately measure. 
Comparison among the Michael-type addition hydrogels of the same polymer weight 
percentage indicated the highest modulus for PEG-4MAL (Fig. 4.3C), consistent with a 
more fully cross-linked network. Young’s modulus measurement for a variety of polymer 
weight percentages of PEG-4MAL (Fig. 4.3D) varied linearly with polymer weight 
percentage (R2 = 0.96). Importantly, because PEG-4MAL was able to form robust 
networks at low polymer weight percentages, mechanical properties in the range of 
natural collagen gels used for 3D cell culture and in vivo delivery was possible with 4% 
and 5% PEG-4MAL gels while other higher percentage gels were much stiffer. 
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Figure 4.3 Michael-addition hydrogel reaction and material properties characterization 
(A) 4-arm PEG macromer functionalization with RGD peptide at 10 and 60 mins, 4 and 
400 mM TEA in PBS with varying end-group to thiol molar ratio. (B) Influence of 
polymer weight percentage on equilibrium swelling ratio (Qm) for networks made from 
PEG-4MAL, PEG-4A, PEG-4VS, or linear PEG-DA. (C) Young’s modulus measured by 
AFM for 10% (wt/v) PEG gels. (D) Young’s modulus measured by AFM for PEG-4MAL 
gels with varying polymer weight percentage and for 3 mg/mL collagen-I gel. 




To examine the ability of these hydrogels to support cellular activities, murine 
C2C12 myoblast cells were encapsulated in 3 mg/mL collagen-I and 10%, 7.5%, 5%, 4%, 
and 3% (wt/v) PEG hydrogels (50 µL) incorporating 2.0 mM RGD peptide at 3 x 106 
cells/mL and cultured for 3 days followed by Live/Dead staining (Invitrogen) (Fig. 
4.4A). Due to differential swelling ratios and gelation times (cells settling out of gel to 
bottom of well), post-encapsulation cell density varied among groups. PEG-4A and PEG-
DA with cells did not form gels at polymer weight percentages below 7.5%. Three 
percent PEG-4MAL gels containing cells dissipated before 3 days due to cell-mediated 
proteolysis and were not imaged. A large fraction of cells in all conditions stained 
positive for viability. More dead cells were visible in 4% PEG-4VS gels and in 10% 
PEG-DA gels than other conditions. Cell spreading was the highest in 4% PEG-4MAL 
and was the most comparable to the natural collagen matrix. Encapsulated cells were also 
assayed for metabolic activity at 3 days by MTS assay. C2C12 cells encapsulated in 
PEG-4MAL and PEG-4VS had metabolic activities similar to controls consisting of 
samples with same number of cells seeded at day 0. Collagen gels had metabolic activity 
significantly higher than the initial seeding density indicating signs of cell proliferation. 
4% PEG-4VS, PEG-DA, PEG-4A, gels had significantly lower metabolic activities 
compared to controls, indicating cell loss attributed to cyto-toxicity.  Notably metabolic 
activity was only 60% of the control in PEG-DA and PEG-4A gels. Exposure to high 
TEA concentrations, free radicals, and UV light could be responsible for the lower 
metabolic activity/viability. We observed that high TEA concentrations (400 mM) alone 
had negative effects on sensitive cells types such as endothelial cells (HUVEC) assayed 
by MTS assay (Fig. 4.5). 
Lastly, we examined the potential for in situ application of PEG-4MAL as a 
myocardial surface patch. A 5% PEG-4MAL precursor solution with addition of labeled 
FITC-PEG-MAL for visualization was mixed and pipetted directly onto the pericardium 
of a rat heart. The hydrogel formed rapidly and was observed to bond with the contacting 
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tissue. Hematoxylin and eosin staining showed a continuous interfacial surface between 
the hydrogel and the myocardial wall (Fig. 4.4B). Fluorescence microscopy of the 
hydrogel-tissue interface revealed excellent hydrogel incorporation into the tissue with a 
penetration depth of approximately 50 µm. The FITC signal penetration was not due to 
diffuse or unbonded FITC-PEG-MAL which would have washed out during the multiple 





Figure 4.4 Hydrogel cyto-compatibility and tissue integration properties (A) Live/Dead 
staining of C2C12 murine myoblasts encapsulated in PEG hydrogels of varying polymer 
weight percentage compared to collagen-I gel (3 mg/mL). Cross-linked hydrogels could 
not be generated for low percentage PEG-4A and PEG-DA gels. Scale bar = 100 µm. 
Inset false color higher magnification showing individual cell spreading. MTS metabolic 
activity assay of encapsulated C2C12 cells indicates viability similar to number of cells 
seeded for PEG-4MAL and PEG-4VS, with PEG-4A and PEG-DA approximately 60% 
(B) H&E stain of PEG-4MAL matrix cross-linked directly on mouse myocardial wall. 
PEG-4MAL matrix incorporating 1% polymer substitution FITC-PEG-MAL cross-linked 
directly on mouse myocardial wall, counterstained with Alexa-Fluor 594 phalloidin and 
DAPI. Fluorescence intensity profiles for FITC-PEG-MAL and 594-phalloidin illustrate a 
physical incorporation depth of hydrogel into tissue of approximately 50 µm. 
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The PEG-4MAL, PEG-4VS, and PEG-4A 4-arm macromers are identical in 
structure aside from the reactive end groups and should form similar networks if all the 
available reactive groups are able to combine with the dithiol cross-linker at 100% 
efficiency. However, the considerable differences in RGD incorporation, swelling 
behavior, gelation time, Young’s modulus, and cell viability observed among the 
different Michael-type addition reactive groups indicates that hydrogel cross-linking 
efficiency and gelation are markedly different among the reactive macromers. Taken 
together, our results indicate that PEG-4MAL exhibits faster reaction kinetics and tighter 
network structure than PEG-4A or PEG-4VS. Additionally, we found that the PEG-
4MAL cross-linking reaction requires two orders of magnitude less TEA than either 
PEG-4A or PEG-4VS. Furthermore, we were able to create hydrogels of lower polymer 
weight-percentage and with a wider range of Young’s moduli than gels based on PEG-
DA, PEG-4A, or PEG-4VS. Importantly, low polymer weight percentage PEG-4MAL 
gels could be formed with mechanical properties that ranged in the low modulus 
environment of naturally-derived extracellular matrices such as type I collagen. These 
lower polymer weight percentage PEG-4MAL networks promoted increased spreading of 
encapsulated cells which could not be recapitulated in the other macromers. Many 
published articles report gelation times on the order of 15-60 minutes for Michael-
addition crosslinking [98, 245, 256, 257] which is unwieldy for in situ clinical application 
where the gel must set up quickly and not flow from the administration site or be diluted 
with fluid. We found that  PEG-4MAL hydrogels had significantly faster cross-linking 
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times of 1-5 minutes depending on the weight percentage and hold strong potential for 
clinical use with in situ gelation. 
 
Conclusion 
These results establish PEG-4MAL hydrogels with improved cross-linking 
efficiency, bioligand incorporation, encapsulated cell viability and reaction time scales 
appropriate for in situ gelation as versatile synthetic analogs of extracellular matrices for 
basic cell studies and regenerative medicine applications. 
 
Methods 
Measure-iT Thiol Assay 
Serial dilutions of end-group functionalized PEG macromers were added to a 
standard concentration of 10 mM GRGDSPC in 4 or 400 mM TEA in PBS. At specified 
time points, the reaction was quenched by 1:100 dilution in water. One hundred 
microliters of PEG-RGD plus 10 µL of thiol-quantitation reagent was added per well of a 
black 96-well plate and read using a microplate reader. Dilutions of RGD in 4 or 400 mM 
TEA in PBS were used as standards. All samples were measured in triplicate. 
 
PEG macromer synthesis 
For PEG-4VS, 4-arm PEG (Sunbright PTE-20000, MW=19858; NEKTAR 
Therapeutics, San Carlos, CA) was functionalized at the OH-termini with divinyl sulfone 
(Sigma-Aldrich) as described previously [131, 256]. In brief, PEG-4VS was synthesized 
by reacting a dichloromethane solution of the PEG-OH (previously dried over molecular 
sieves) with NaH under argon gas and then, after hydrogen evolution, with diVS (molar 
ratios: OH 1 / NaH 5 / diVS 50), at room temperature for 3 days, under argon with 
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stirring. The resulting solution was neutralized with 99.8% acetic acid and filtered 
through filter paper until clear. VS-functionalized PEG was then precipitated in ice-cold 
diethyl ether, washed, and re-dissolved in dichloromethane; this cycle was repeated twice 
to remove all excess diVS, and the PEG-4VS was finally dried under vacuum. The 
success of VS conversion on the OH-termini was confirmed by NMR spectroscopy to be 
90-95% as previously described [131]. 
For PEG-DA hydrogels, the protease degradable peptide cross-linker 
GCRDVPMSMRGGDRCG (VPM) was incorporated into the backbone of the PEG-DA 
macromer as previously reported [249]. PEG-diacrylate (3400 MW, Laysan Bio) was 
reacted with the VPM peptide at a 2:1 PEG to peptide molar ratio in PBS + 400 mM TEA 
for 6 hours at 1 mg/mL PEG concentration to create the macromer acrylate-PEG-VPM-
PEG-acrylate. The reaction product was dialyzed three times against di-H2O and 
lyophilized for storage. The cell adhesion peptide GRGDSP was similarly conjugated to 
PEG-acrylate with the amine-reactive molecule acrylate-PEG-NHS (Laysan Bio) in 50 
mM sodium biocarbonate buffer at 1:2 molar ratio for 6 hours followed by dialysis 
against di-H2O and lyophilization. PEG-peptide conjugates were confirmed by molecular 
weight increases of products vs. reactants on SDS-PAGE.  
 
PEG Hydrogel Formation 
PEG-DA gels were formed by adding 2 mM acrylate-PEG-RGD with various 
polymer weight percentage solutions of acrylate-PEG-VPM-PEG-acrylate in PBS + 
0.05% Irgacure 2959 (Ciba) photoinitiator and exposure to 10 mW/cm2 UV light for 10 
minutes. Michael-type addition PEG hydrogels (PEG-4A, PEG-4VS, PEG-4MAL) were 
formed by reacting 4-arm functionalized PEG-macromer with the cell-adhesion peptide 
GRGDSPC followed by cross-linking with the protease degradable peptide VPM at 
stoichiometrically balanced 1:1 cysteine to remaining reactive group molar ratio. For 
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most experiments, PEG-4A and PEG-4VS were reacted in PBS + 400 mM TEA, pH 7.4, 
whereas PEG-4MAL was reacted in PBS + 4 mM TEA, pH 7.4. 
 
Mass Swelling Ratio 
Six hydrogels per condition were formed in 9 mm diameter x 1 mm deep silicone 
isolator wells sandwiched between two coverslips coated in Sigmacote® (Sigma-
Aldrich). After cross-linking, hydrogels were allowed to freely swell in di-H2O for 24 
hours and the swollen hydrogel mass measured. Hydrogels were then snap-frozen in 
liquid N2 and lyophilized followed by dry mass measurement. The mass swelling ratio is 
reported as the ratio of swollen mass to dry mass. 
 
AFM Modulus Testing 
Using an MFP-3D-BIO atomic force microscope (Asylum Research; Santa 
Barbara, CA), samples were probed under fluid conditions (ultrapure-H2O) using a 
pyramidal tipped-silicon nitride cantilever (Bruker, Camarillo, CA). Cantilever spring 
constants were measured prior to sample analysis using the thermal fluctuation 
method,[258] with nominal values of 20-30 mN/m. The force-indentation curve was 
obtained for each measurement and then analyzed with a Hertzian model for a pyramidal 
tip (Wavemetrics, IgorPro software routines) from which the Young’s modulus values 
were calculated. The sample Poisson’s ratio was assumed as 0.33, and a power law of 2.0 
for the sample indentation distance was used to model tip geometry. All AFM 
measurements were made using a cantilever deflection set point of 100 nm, and the rate 
of indentation was 22.86 µm/s. 100 nm was chosen as the cantilever deflection set point 
for mechanical testing, as this corresponds to loading forces of approximately 5-10 nN.  
This scale of probe conditions is within the range of the traction forces applied through 
single adhesions to the ECM, and is thus a relevant range for mechanical testing [259], 
 78 
[260]. Furthermore, similar testing forces have been recently published for PEG-
containing hydrogels [261]. A minimum of 9 independent measurements was obtained 
and analyzed for each sample condition. 
 
Cell Encapsulation 
Murine C2C12 myoblast cells (ATCC) were encapsulated in 3 mg/mL collagen-I 
or 10%, 7.5%, 5%, and 4% (wt/v) 50 µL PEG matrices with 2 mM RGD at 3 x 106 
cells/mL and cultured in DMEM + 20% fetal bovine serum + 1% penicillin/streptomycin. 
PEG-4A and PEG-4VS were cross-linked with VPM peptide for 1 hour in 400 mM TEA. 
PEG-4MAL was cross-linked with VPM peptide for 10 minutes in 4 mM TEA. PEG-DA 
was cross-linked by addition of 0.05% Irgacure 2959 and 10 min exposure to a UV lamp 
at 10 mW/cm2. At 3 days post-encapsulation, culture media was replaced with PBS 
containing 2 μM calcein AM and 4 μM ethidium homodimer-1 for Live/Dead staining. 
Hydrogels were incubated in Live/Dead stain for 30 minutes and visualized on a Nikon-
C1 laser scanning confocal microscope with a 20X air objective. Z-stack projections 
through a 100 µm thick section of the swollen hydrogel were rendered. For MTS 
measurements, gels containing cells were degraded with 1 mg/mL collagenase 1 in PBS 
to eliminate differences due to diffusivity in the gels followed by incubation for 4 hours 
with MTS reagent (Promega). For direct effects of TEA on cell viability, human 
umbilical vein endothelial cells (HUVEC, Lonza) were suspended in PBS containing 0, 
4, 40, or 400 mM TEA pH 7.4 for one hour. The cells were subsequently examined for 
differences in metabolism by MTS assay (Promega). 
 
Myocardial Patch 
Fifty microliters of 5% PEG-4MAL with 2 mM RGD hydrogel and 1% dry 
weight substation of labeled FITC-PEG-MAL for visualization in 4 mM TEA was mixed 
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and pipetted directly onto the pericardium of a freshly excised rat heart. The tissue was 
fixed and processed for preservation in Immuno-Bed (Polysciences) plastic resin, 
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IN VIVO ISLET GRAFTING AND VASCULARIZATION 
POTENTIAL OF ENGINEERED HYDROGELS IN HEALTHY RATS 
 
Summary 
 Polyethylene glycol (PEG)-based matrices were designed to support pancreatic 
islet encapsulation and in vivo vascularization. VEGF, a potent stimulator of 
angiogenesis, was tethered to the matrix by pre-functionalization with 4-arm PEG 
maleimide.  The lifetime of VEGF signal in the matrix was greater than two weeks in 
vitro and one week in vivo. Isolated rat islets encapsulated in PEG-maleimide hydrogel 
matrices remained viable for at least 5 days in culture, secreted insulin, and sprouted 
endothelial processes when stimulated with VEGF. Islets transplanted in the small bowel 
mesentery of healthy rats with the PEG-4MAL matrix as a delivery vehicle grafted to the 
host tissue and intra-islet endothelial beds were re-perfused as visualized by FITC-lectin 
perfusion staining. Islets encapsulated in photo-cross-linked PEG-diacrylate showed low 
insulin secretion in vitro and poor grafting potential in vivo. These results establish the 
validity of PEG-4MAL engineered matrices as a vascular-inductive cell delivery vehicle 




Type 1 diabetes affects one in every 400-600 children in the US and as many as 
three million Americans in total. Standard therapy with exogenous insulin is burdensome, 
associated with significant hypoglycemia risk, and only partially efficacious in 
preventing long term complications. 
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Pancreatic islet transplantation has emerged as a promising therapy for type 1 
diabetes, a safer alternative to whole organ transplantation and a long-term replacement 
for exogenous insulin therapy. However, this cell-based biological therapy is significantly 
limited by acute and long-term rejection of allografted cells due in part to inadequate 
revascularization of transplanted islets resulting in reduced islet viability, function, and 
engraftment. Biomaterials have long been investigated as a means to improve or augment 
islet and beta cell transplants. There are two distinct approaches to islet encapsulation: 
one strategy is to encapsulate donor cells in a barrier material that isolates them from the 
host immune system but allows for passive transport of oxygen, glucose, insulin, and 
other small molecules. The alternative is the administration of immuno-suppressive drugs 
to prevent rejection by host lymphocytes of islets infused directly into host organs such as 
the liver or kidney, sometimes augmented by an engineered delivery vehicle. 
West and Anseth developed UV-initiated free radical polymerization schemes for 
crosslinking PEG hydrogels and proved their efficacy for cell encapsulation and tissue 
engineering studies [262-266]. Hubbell published early work showing islet cell survival 
in encapsulating PEG hydrogel [267] and later Anseth showed promotion of pancreatic 
beta cell [268-270] and islet activity [130, 271, 272] in PEG hydrogels. 
We engineered PEG-4MAL hydrogel matrices as an islet engraftment and 
vascularization delivery vehicle. The PEG-4MAL hydrogel chemistry is advantageous for 
cell delivery due to the mild cross-linking that occurs rapidly enough for in situ delivery, 
while easily lending itself to “plug-and-play” design variations. Combined with a novel 
transplantation model, we developed a robust strategy incorporating advanced 
biomaterials for rapid vascularization of islet cell grafts. The innovation in this project 
lies in the engineering of a bioactive hydrogel delivery vehicle that promotes controlled 
vascularization of transplanted pancreatic islets via on-demand release of angiogenic 
factors.  Based on previous reports that sustained delivery of VEGF from a PEG hydrogel 
[105] results in stable vasculature, we hypothesized that controlled/sustained presentation 
 82 
of angiogenic cues within this bioartificial matrix would enhance the vascularization and 
function of transplanted islets. This strategy is fundamentally different from other 
biomaterial approaches (reviewed in [197, 273]) focusing on coatings for 
immunoprotection [130, 272, 274, 275] and simple matrix carriers that serve as growth 
factor reservoirs [136, 138, 182, 183, 188, 189] but do not control the delivery profile of 
bio-therapeutics. By controlling the delivery of angiogenic factors and tissue invasion in 
an on-demand fashion, we hypothesize that these engineered delivery matrices will 
promote rapid vascularization of the islets to effectively support islet viability and 
function. Another innovative feature is the development of a novel implantation site in 
the small bowel mesentery. In contrast to other commonly used implant sites such as 
subcutaneous space, epididymal fat pad, and renal subcapsule [276, 277], we explore the 
small bowel mesentery as a novel islet implantation site with significant vascularization 
potential, accessibility, and direct supply to the hepatic portal vein. The liver is 
significant sink of physiologically producted insulin where circulating blood glucose is 
quickly converted to stored glycogen. By transplanted islets in a vascularized bed located 
upstream from the liver, small amounts of insulin produced may have a greater effect on 
reducing blood sugar as the insulin will be more concentrated when it reaches the liver 
than had it been diluted through the peripheral circulation if the islets were transplanted 
in more remote sites such as subcutaneously. 
 VEGF was selected as the angiogenic agent due to multiple reports indicating that 
VEGF-A augments islet vascular bed formation, insulin production, and islet cell mass 






We engineered PEG-based hydrogels cross-linked by maleimide Michael-addition 
chemistry as described in the previous chapter. To form bioactive hydrogels, a 4-arm 
PEG-maleimide macromer was first reacted with the cell adhesive sequence GRGDSPC 
followed by crosslinking into a gel with a cysteine-flanked proteolytically degradable 
peptide sequence GCRDVPMSMRGGDRCG (VPM). VEGF165, a homodimer protein 
with C-terminal unpaired cysteine, was physically incorporated into the gel by pre-
incubation with the PEG-4MAL macromer prior to crosslinking. Conjugation of RGD 
and VEGF to PEG-4MAL was confirmed by increases in molecular weight on SDS-
PAGE gels (Fig. 5.1 A). We compared the performance of RGD/VEGF functionalized 
PEG-4MAL gels with previously described PEG-DA gels (Chp. 3). 
We examined the release profile of VEGF from PEG-4MAL hydrogel in vitro and 
in vivo (Fig. 5.1 B-D). VEGF was labeled with VivoTag-S 750 (Perkin Elmer), an amine-
reactive near-infra-red fluorochrome coupled via an NHS ester linkage to make VEGF-
750. After purification from free dye with Zeba desalting columns, conjugation of 
VivoTag-S 750 to VEGF was confirmed by SDS-PAGE and infrared imaging of the 
labeled protein band. Cylindrical PEG-4MAL hydrogels (9mm x 1 mm) containing 10 
µg/mL VEGF-750 were cast in silicon molds, floated in media baths of PBS, and imaged 
on an IVIS Lumina (Caliper Life Science) in vivo imaging system due to its near-IR 
imaging and analysis capabilities. Collagenase-I enzyme was added to half of the samples 
and gels were imaged daily for VEGF-750 release into the media over two weeks. The 
collagenase-treated samples degraded completely overnight and released all of their 
VEGF into the media. Samples in PBS retained a strong IR signal confined to the implant 
volume with 40% signal remaining at 14 days (τ1/2 = 2.67 days). In a separate experiment, 
PEG-4MAL hydrogels containing VEGF were incubated in PBS or collagenase and 
samples from the media were analyzed for VEGF content by ELISA. VEGF was released 
from the hydrogel upon proteolytic degradation but not when incubated in PBS. This 
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result confirms the measured IR fluorescence was a result of VEGF release and not free 
dye.  
VEGF release from the hydrogel was also measured in vivo (Fig. 5.2). Gels with 
VEGF were implanted according to the surgical model developed for transplantation of 
pancreatic islets into the small bowel mesentery. PEG-4MAL hydrogels (100 µL) with 10 
µg/mL VEGF-750 and 2 mM RGD were cast directly onto the small bowel mesentery. 
Animals were imaged by IR fluorescence through the abdominal wall at day 0, 1, 3, and 7 
for VEGF-750 fluorescence with an IVIS Lumina (Caliper Life Science) in vivo imaging 
system. VEGF-750 signal bright enough to be imaged through the abdominal wall of rat 
persisted in vivo for at least 7 days with an approximate in vivo half life of 1.4 days. For 
comparison, VEGF delivered by diffusion release in calcium cross-linked alginate gels 
had no signal remaining at 3 days. This result indicates that the PEG-4MAL matrix can 





Figure 5.1 VEGF-modified PEG-4MAL hydrogel schematic and growth factor release. 
(A) VEGF modified by PEG-4MAL displays increased molecular weight on a western 
blot. RGD and VEGF are first functionalized with PEG-4MAL before crosslinking into a 
hydrogel with cysteine-flanked MMP-degradable cross-linker. (B) VEGF released from 
PEG-4MAL gels into the media measured by ELISA from gels treated with PBS (-○-) or 
Collagenase-I (-●-). (C,D) IVIS fluorescence intensity quantification of VEGF-750 




Figure 5.2 In vivo release of VEGF from PEG-4MAL vs. alginate. (A) IVIS imagery of 




Next we examined the effects of encapsulation in bulk PEG-4MAL and PEG-DA 
hydrogel on isolated islets. Pancreatic islets were isolated from healthy male Lewis rats 
by collagenase digestion of the pancreas and Ficoll density gradient centrifugation (Fig. 
5.3 A). Isolated islet structures were examined for purity by dithizone staining for zinc in 
beta cells (Fig. 5.3 B) and immunostaining for insulin (Fig. 5.3 C). One set of islets was 
isolated from rats injected intravenously with FITC-lectin to visualize the intra-islet 
vascular system (Fig. 5.3 D). Islets were evaluated for survival after the encapsulation 
process in PEG-4MAL + 2 mM RGD gels by Live/Dead staining at 0, 3, and 5 days post-
encapsulation (Fig. 5.4 A). Viability was high for islets at all three time points. Islets 
were also evaluated for metabolic activity by MTS assay (Fig. 5.4 D). 
To evaluate endocrine function, islets were encapsulated in RGD-functionalized 
hydrogels PEG-4MAL, PEG-4MAL + VEGF, PEG-DA, and PEG-DA + VEGF. 
Collagen-I gels and free islets were used as positive control groups. Hydrogels containing 
islets were cultured in RPMI-1640 media supplemented with 10% FBS. At 48 hours post-
encapsulation the media was measured for insulin production by ELISA (Fig. 5.5). Islets 
in PEG-DA gels produced little to no insulin, but islets in PEG-MAL produced 70 ng/mL 
per islet or 120 ng/mL per islet with addition of VEGF which was equivalent to free 
islets. 
We observed islets sprouting cellular processes several hundred microns into the 
surrounding matrix in PEG-4MAL gels incorporating VEGF (Fig. 5.4 B). These 
sprouting structures stained positive with lectin and some of them developed lumens 
suggesting that they are endothelial sprouts originating from intra-islet endothelial cells. 
The sprouting behavior was investigated with respect to choice of adhesive peptide (Fig. 
5.4 C). Hydrogels containing the laminin-derived peptide IKVAV were compared to 
fibronectin-derived RGD, collagen-I gels, un-functionalized PEG-4MAL gels, and PEG-
4MAL gels with RGD but not VEGF. Samples were scored according to percentage of 
islets in the gel that were exhibit sprouting behavior at 48 hours. Collagen-I performed 
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the best with 95% of islets sprouting while RGD at 65% was significantly better than 
IKVAV at 45%. Islets in un-functionalized gels failed to sprout. Cell migration in RGD 





Figure 5.3 Islet isolation procedure. (A) Surgical procedure for filling the pancreas with 
collagenase enzyme and density gradient separation of islets from other cells. (B) Isolated 
islets stain positive with dithizone as a quality check. (C) Isolated islets stain positive for 
insulin (D) The intra-islets vascular bed is visible in islets isolated from animals perfused 
with FITC-lectin. (E) For quantification, islets were pooled in a 100 mm petri dish, 




Figure 5.4 Islet encapsulation in PEG-4MAL hydrogel. (A) Islets encapsulated in PEG-
4MAL gel maintain high viability over at least 5 days in culture. (B) Islets encapsulated 
in hydrogel sprout endothelial tubes in the presence of RGD and VEGF. (C) 
Quantification of islet sprouting as a function of adhesive ligand. (D) Cells encapsulated 
in PEG-4MAL maintain metabolism comparable to collagen-1 gel. 
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Figure 5.5 Insulin production of islets encapsulated in bulk hydrogels. (A) Insulin 
production per islet rises over time in culture, addition of VEGF improves insulin output. 




The in vivo vascularization and grafting potential of pancreatic islets encapsulated 
in PEG-4MAL and PEG-DA matrices to the small bowel mesentery was investigated 
with a surgical model. Islets were isolated from 2 donor pancreases to generate 
approximately 1500 islets for each recipient. Syngenic inbred Lewis rats were used for 
both the donor and recipient animals to eliminate risk of a tissue-type mismatch graft 
rejection. During the surgical procedure a small section of small bowel was gently 
exteriorized through a midline incision (Fig. 5.6 A). Two 100 µL 4% PEG-4MAL 
hydrogels with 2 mM RGD and +/- 10 µg /mL VEGF containing approximately 750 
islets each were pipetted onto the surface of the clear mesenteric tissue and allowed to 
cross-link for 10 minutes (Fig. 5.6 B) before re-insertion of the small bowel into the 
abdominal cavity and wound closure. 
PEG-DA was also evaluated as an islet transplantation matrix. PEG-DA proved to 
be unwieldy for in situ polymerization due to the low viscosity of the precursor solution 
and inconsistent gelation under UV light at the tissue site.  Therefore the PEG-DA 
matrices with encapsulated islets were pre-cast in silicon molds around a small 
polycaprolactone (PCL) rings. The preformed constructs were sutured in place to the 
small bowel mesentery through the PCL ring as an anchor point (Fig. 5.6 C,D). The 
PEG-4MAL and PEG-DA matrices were tested in vivo in separate studies. 
In both studies, islets were transplanted in gels with and without VEGF as well as 
compared to calcium cross-linked alginate gels. Animals were sacrificed at 1 and 4 weeks 
to evaluate grafting and vascularization behavior. By one week new vessels could be 
clearly seen growing into the surface of the hydrogels from surrounding tissue in both 
PEG-DA and PEG-4MAL (Fig. 5.7). By 4 weeks a strong and dense vascular in-growth 
response was evident, and especially apparent in the PEG-4MAL + VEGF group. The 
vascular response to the PEG-DA gels appeared to be limited to the surface of the 
implant (Fig. 5.8) whereas PEG-4MAL had vessels reaching throughout the interior of 
the implant (Fig. 5.9).  New vessels were not visible in the alginate groups. For 
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histological preparation and to prove patency of vascular in-growth, FITC-lectin was 
injected intravenously in the PEG-4MAL groups and allowed to circulate before the 
animals were euthanized. 
Explanted tissue samples from the PEG-4MAL hydrogels were stained as whole 
mounts for insulin and imaged on a fluorescent stereoscope to examine overall islet 
survival (Fig 5.10). On average 65 independent insulin-positive structures per field were 
visible in PEG-4MAL + VEGF gels, 42 for PEG-4MAL without growth factor, and 1-2 
for alginate. Explants from both PEG-4MAL and PEG-DA were embedded in Immuno-
Bed plastic resin, sectioned at 2 µm and, analyzed histologically by hematoxylin and 
eosin stain (Fig. 5.9 A), Masson’s trichrome stain (Fig. 5.9 B), and immuno-fluorescence 
(Fig. 5.11). All islets in PEG-DA gels appeared necrotic with few discernable nuclei and 
stained very weakly or negatively for insulin. The primary host response to the PEG-DA 
gel was fibrous encapsulation with vascularization limited to the implant periphery and 
significant CD-68 positive macrophage activity in the fibrous capsule. 
Fluorescence microscopy imaging of the PEG-4MAL implants for insulin, FITC-
lectin, and nuclei revealed many surviving islets with signs of initial early 
revascularization at 1 week which improved to robust reperfusion of the intra-islet 
endothelial bed similar to native islets in the pancreas by 4 weeks. Positive staining for 
lectin in intra-islet capillaries indicated that the vessels were well perfused in connection 
with the host circulatory system. A higher density of islets was apparent in the PEG-
4MAL + VEGF group than in the PEG-4MAL, but all surviving islets in both groups 
appeared to be vascularized. H&E and trichrome staining revealed a degree of monocyte / 
macrophage activity remodeling in the PEG-4MAL matrix. Trichrome staining also 
revealed new vessels to be associated with connective tissue and erythrocytes were 
confined to the interior of endothelial tubes. 
To quantify differences in vascularization response to PEG-4MAL hydrogels with 
and without VEGF and with and without islets, animals were perfused with microfil 
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vascular contrast agent to quantify vascularization by microCT (Fig. 5.12). PEG-4MAL 
hydrogels containing RGD, +/-VEGF and +/- islets were cross-linked directly on the 
small bowel mesentery of healthy rats. At 4 weeks the vascular system of the animals was 
perfused with microfil polymerizing contrast agent as previously reported [249]. After 24 
hours to cure, the tissue at the implant site was explanted, fixed overnight, and scanned in 
a SCANCO µCT 40 system at medium resolution. Vasculature was quantified based on 
vascular volume percentage of total explant volume, vessel thickness, and connectivity.  
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Figure 5.6 Hydrogel implantation procedure. (A) Loop of exteriorized small bowel with 
mesentery, forceps point to implantation site. (B) PEG-4MAL hydrogel formed directly 
on the mesentery tissue (C) PEG-DA hydrogel pre-cast construct sutured in place to 






Figure 5.7 Macroscopic vascular response to PEG-4MAL islet transplantation with and 




Figure 5.8 Response to islets transplanted in PEG-DA hydrogel. (A) Vascular response 
visualized with epi-illumination and back illumination. (B) Immuno-fluorescence 
staining of section of explanted PEG-DA for insulin and CD-68. (C) Pre-implantation 
density of islets in PEG-DA construct for comparison. (D) Compost H&E stain showing 





Figure 5.9 Response to islets transplanted in PEG-4MAL hydrogel. (A) H&E of 
transplant site at 1 and 4 weeks. (B) Trichrome stain of implant site at 4 wks illustrating 
vascular response. (C) Vessel ingrowth quantified by counting vascular structures 
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Figure 5.10 Whole mount immuno-fluorescent stain for insulin and quantification islet 
structures in PEG-4MAL gel explants. 
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Figure 5.11 Immuno-fluorescent histological sections of grafted islets in PEG-4MAL gel 
explants. (A) Native islet in the pancreas with lectin staining capillary bed. (B) H&E of 




Figure 5.12 MicroCT tomograms and analysis of PEG-4MAL gels implanted in small 
bowel mesentery. (A) Renderings of small bowel mesentery vasculature with blue line 




The release profile of VEGF from the hydrogel as measured by both ELISA and 
near-IR fluorescence of labeled VEGF indicates that the growth factor is sequestered 
within the matrix and the predominant mode of release is through proteolytic degradation 
of the gel and not by diffuse release. The extremely rapid release and degradation of the 
collagenase-treated gels is a result of both an artificially high concentration of 
collagenase and the rapid-degradation profile of the chosen cross-linker peptide 
sequence. We also have shown that VEGF is conjugated to the PEG-4MAL macromer 
based on increased molecular weight after the addition reaction. Therefore there is 
considerable evidence to substantiate the claim the growth factor is covalently bound to 
the matrix and not just entrapped within the nano-porous polymer network. 
Pancreatic islets encapsulated in photo-polymerized RGD functionalized PEG-
DA hydrogel failed to produce insulin and showed low viability. While it has been 
postulated that beta cells encapsulated in photo-polymerized hydrogel have low viability 
due to a lack of ECM and cell-cell interactions [281], it is also likely that toxicity to both 
the free-radical cross-linking process and the bulk properties of the PEG-DA hydrogel 
contribute to poor islet compatibility. In contrast, islets encapsulated in PEG-4MAL 
hydrogel had higher viability and produced insulin similarly to free islets. This is likely 
due to milder crosslinking reaction of the PEG-4MAL hydrogel as previously shown in 
Chapter 4. Addition of VEGF to the matrix improved in vitro insulin production in both 
PEG-4MAL and PEG-DA. It has been reported that VEGF-A co-localizes with cells 
expressing insulin in islets indicating that beta cells express VEGF [177]. Additionally 
VEGF receptor 2 (VEGFR2) is more highly expressed in the microvasculature of islets 
compared to other capillaries in the exocrine pancreas [177]. VEGF-deficient islets result 
in reduced insulin output [177]. These factors lend support to the idea that VEGF 
signaling is intrinsically important to the homeostasis and health of the islets.  
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Islet sprouting behavior of lectin-positive cells similar to that observed in our 
cultures has been observed by Stupp and colleagues in peptide amphiphile hydrogels on a 
similar time frame (day 3 post-encapsulation) [173]. Stupp also reports a similar 
percentage of sprouting islets in matrices augmented by addition of VEGF and FGF2. 
This repetition of results indicates that isolated islets in synthetic matrix systems can 
undergo angiogenic sprouting under the right conditions. The RGD adhesive ligand 
initiated significantly more sprouting behavior than laminin-derived IKVAV. RGD is a 
preferential ligand for αvβ3 integrin, highly expressed on sprouting endothelial cells 
while IKVAV does not ligate αvβ3 integrin. Therefore it is plausible that endothelial cell 
sprouting was improved in the RGD matrix over IKVAV due the presence of endothelial 
cell-specific adhesion ligands. Islets in the artificial matrix did not sprout as well as in 
natural collagen matrix which has higher density, variety, and stronger-affinity adhesive 
ligands. Additionally the sprouting behavior is an indication that the islet endothelial cells 
are able to degrade the protease-sensitive peptide cross-linker effectively. It has been 
previously shown that intra-islet endothelial cells play an important role in transplanted 
islet revascularization [178, 282, 283]. 
 Both PEG-DA and PEG-4MAL matrices were tested in vivo for islet delivery and 
grafting potential. PEG-DA proved unsuitable for in situ delivery so pre-cast matrices 
were sutured to the graft site in the small bowel mesentery instead of cross-linked in 
place. The host tissue failed to significantly degrade the PEG-DA hydrogel and instead 
responded with fibrous encapsulation. The islets in the PEG-DA hydrogel which 
appeared dead or missing in the histology analysis most likely succumbed to oxygen and 
nutrient deprivation if the encapsulation process itself was not too toxic. The reason for 
the host fibrous encapsulation response to the PEG-DA is two-fold. One reason is that the 
host tissue was unable to degrade the higher density PEG-DA matrix in the small bowel 
mesentery site. Although we previously observed degradation of the PEG-DA matrix in 
subcutaneous implants this trend does not necessarily carry over to other implant sites. 
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The other reason for fibrous encapsulation is that without a cohesive interface between 
the matrix and host tissue, the micro-motion of the implant in addition to local 
inflammation and tissue damage from the suturing resulted in an inflammatory foreign 
body response. 
 In contrast to PEG-DA, PEG-4MAL matrices were far more suitable for in situ 
delivery, readily adhering to the mesenteric tissue during the gelation process without any 
need for suture or other foreign material. The early vascular ingrowth (7 days) appeared 
leaky from diffuse lectin staining but not altogether unexpected in VEGF-induced 
angiogenesis. However the VEGF-induced vessels persisting at 4 weeks had a more 
stable appearance with lectin staining confined to the interior of vessels coinciding with 
the IVIS imaging evidence that VEGF in vivo release was depleted by 1 week.
 Without long-term and continuous VEGF signaling from the matrix it is plausible 
that intrinsic signaling from the islets themselves is responsible for vessel maintenance 
after the initial VEGF dosage was depleted. We also found surviving islets in matrices 
cast without VEGF suggesting that the signaling from islets alone might be enough to 
induce sufficient vascularization for some islet survival. With microCT scanning we 
attempted to gather quantitative information regarding the vascularization of the PEG-
4MAL implants and the relative signaling contributions of islets vs. VEGF. In scans of 
the implant connected to a large portion of surrounding mesentery it was possible to 
clearly see the vascular growth from surrounding vessels into the implant and observe the 
architecture of the vascular tree. The microCT data indicated that VEGF significantly 
increased the vascularization response in the matrices without islets. But in matrices with 
islets there was no significant difference between with and without VEGF. Paradoxically, 
the microfil casts indicated less vascularization for matrices with islets than for those 
without. This data clearly did not correlate with what was observed in the previous study 
macroscopically and histologically. The microfil injection procedure is somewhat 
tenuous and exhibits significant variability in the quality of the perfusion from one 
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animal to the next. Based on this contradictory evidence we were forced to conclude that 
the reliability of the microCT data may be questionable. A positive indication from the 
microCT tomograms is that the vessels at the implant site at 4 weeks were not permeable 
to the microfil supporting the lectin staining data. Some publications have previously 




 We have successfully delivered islets to the small bowel mesentery in syngeneic 
Lewis rats using VEGF-containing PEG-MAL hydrogels. These hydrogel vehicles 
promoted potent vascularization of the hydrogel and islets. Transplanted islets showed 
high levels of engraftment, were connected to the host vasculature (demonstrated by 
lectin injected into host vasculature), and continued to produce insulin. These results 






As described in Chp. 4, PEG-4MAL 20,000 MW was purchased from Laysan 
Bio. The peptide crosslinker GCRDVPMSMRGGDRCG (VPM) and adhesive ligand 
GRGDSPC were custom synthesized by AAPPTEC. Michael-type addition PEG 
hydrogels were formed by first reacting PEG-4MAL with the cell-adhesion peptide 
GRGDSPC and VEGF for 1 hour in 4 mM TEA in PBS. The precursor solution was 
cross-linked with the cysteine-flanked and protease degradable peptide VPM at 




Human VEGF165 (Invitrogen) was solubilized at 1 mg/mL in PBS. VivoTag-S 750 
(Perkin Elmer) was solubilized in DMSO. 50 molar excess of VivoTag-S 750 was added 
to the VEGF and incubated at room temperature for 1 hour to make VEGF-750. Labeled 
protein was purified from excess dye by 3 successive purification rounds on Zeba Spin 
Desalting Columns 7,000 MWCO (Pierce). Dye concentration in the purified conjugated 
protein sample was measured on a NanoDrop 1000 system using dye extinction 
coefficient of 240,000 M-1cm-1, absorbance of 750 ± 5 nm, and MW of 1183 g/mol. 
VEGF was conjugated to PEG-4MAL by incubation for 1 hour in 10% (wt/vol) PEG-
4MAL in PBS + 4 mM TEA prior to addition to gels. To confirm protein labeling and 
ability of labeled VEGF to react with PEG-4MAL, 100 ng of labeled VEGF-750 was run 
on a NuPAGE Novex 4-12% Bis-Tris SDS-PAGE gel along with PEG-4MAL conjugated 
VEGF-750 unlabeled VEGF and free dye samples. VEGF was confirmed to be labeled 
and free of excess dye as well as conjugated to PEG-4MAL by imaging the gel on a LI-
CORE Odyssey infrared imaging system. 
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In vitro VEGF release 
PEG-4MAL gels containing 10 ug/mL of VEGF-750 cross-linked by VPM 
peptide were pre-cast in 9 mm x 1 mm cylindrical silicon molds. Gels were floated in 
baths of PBS and incubated at 37°C for 24 hours to fully swell. At 24 hours, a final 
concentration of 0.1 mg/mL of Type I Collagenase was added to half the samples were. 
For sampling of VEGF released to the media, 5 µL samples of the media bath were taken 
every 2 hours during the first day. Media samples were measured for VEGF content by 
ELISA using the human VEGF ELISA kit (invitrogen) and compared to standard samples 
of diluted VEGF in PBS equivalent to a fully degraded gel releasing all of the loaded 
VEGF. Samples were also imaged daily on an a 700 series Xenogen IVIS machine at 710 
nm excitation, 780 nm emission and 60 s exposure time. Images were quantified for 
background subtracted average photon counts per ROI. 
 
In vivo fluorescence imaging 
PEG-4MAL hydrogels (100 uL) with 10 ug/mL VEGF cross-linked by VPM were 
adhered to the small bowel mesentery of Lewis rats fed a low-alfalfa diet to minimize 
tissue auto-fluorescence. Anesthetized rats were imaged at 710 nm excitation, 780 nm 
emission, and 60 s exposure time in a 700 series Xenogen IVIS machine a 0, 2, and 7 
days post-transplant. Images were analyzed for background-subtracted average photon 
counts within an ROI gated over the implant site. 
 
Islet isolation 
Modified from [285], rats were anesthetized with isoflurane and euthanized by 
exsanguination by severing the vena cava. The distal common bile duct was clamped at 
the insertion point into the small intestine. Ten mL of ice cold Liberase TL collagenase 
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(0.2 mg/mL) in HBSS++ was injected into the proximal common bile duct through a 
catheter pulled from PE-50 polyethylene tubing attached to a 10 mL syringe. The inflated 
pancreas was dissected from surrounding tissue and placed in a container on ice. Vials 
containing pancreases were incubated for 17 minutes in a 37°C water bath. Tissue was 
broken up by pipetting up and down and then incubated for a further 7 minutes. 
Collagenase action was halted by addition of 40 mL ice cold HBSS++ + 10% FBS. Each 
sample was filtered through a mesh sink strainer to remove undigested tissue. Cells were 
collected into a pellet by centrifugation at 800 rpm for 2 minutes followed by two more 
rounds of washing / centrifugation with ice cold HBSS++ + 10% FBS. Cells were 
resuspended in 12 mL of Ficoll density 1.108 followed by layering of 7 mL Ficoll density 
1.096 and 5 mL Ficoll density 1.037. The density gradients were centrifuged at 1100 rpm 
for 30 minutes to separate islets. Separated islets were picked from between the 1.096 and 
1.037 layers with a sterile transfer pipette and washed 3 times in HBSS++. Islets were 
cultured in RPMI-1640 + 10% FBS + 1% Penicillin-Streptomycin in a 37°C, 5% CO2 
incubator. Isolated islets were examined for purity by dithizone staining and counting 
with a macro-photography setup. 
 
Islet culture and in vitro assays 
For in vitro studies, islets were isolated the day before and allowed to recover for 
12-24 hours before encapsulation in hydrogel. Fifty microliter gels of 4% PEG-4MAL + 
2 mM RGD and with or without 10 µg/mL VEGF were cast in the bottom of 8 well Lab-
Tek Chambered Coverglasses (Nunc). Approximately 25-50 islets were encapsulated per 
50 µL gel. Gels were cultured with 500 µL media (RPMI-1640 + 10% FBS + 1% 
Penicillin-Streptomycin) changed daily. PEG-DA gels were formed similarly but were 
cured by a 10 min exposure to 10 mW/cm2 365 nm UV light. Collagen I gels (3 mg/mL) 
were formed from dilution and pH stabilization of 10 mg/mL solubilized rat tail Collagen 
I (BD). Islets were examined daily and observations such as sprouting were recorded. 
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Samples were Live/Dead stained with PBS containing 2 μM calcein AM and 4 
μM  TOTO-3 iodide and imaged with a 20X objective on a Nikon-C1 laser scanning 
confocal microscope. 
Insulin release to the media from encapsulated islets was measured by ELISA 
using the High Range Rat Insulin ELISA kit (Mercodia). Media was changed every day, 
therefore each data point represents total release from the hydrogel over a 24 hour period. 
 
Histology 
Explanted samples from FITC-lectin perfused rats containing hydrogel, islets, and 
tissue were fixed overnight in 10% neutral buffered formalin at 4°C. Samples were pre-
stained (whole mount) for insulin by overnight permeabilization / blocking in 1% HD-
BSA with 0.1% Triton-X 100 in PBS, wash with PBS + 0.1% TWEEN 20, overnight 
incubation with chicken anti-insulin primary antibody (Abcam) in PBS, 3 x 12 hours 
wash with PBS + 0.1% TWEEN 20, overnight incubation with Alexa Fluor 555 goat anti-
chicken secondary antibody (Invitrogen) in PBS, and finally 3 x 12 hours wash with PBS 
+ 0.1% TWEEN 20. Whole mount stains were imaged on a Zeiss fluorescent stereoscope 
for insulin staining before embedding for histology sections. Samples were then 
dehydrated in successive changes of 70%, 95%, 99%, and 3 x 100% ethanol under 
vacuum at 4°C. Dehydrated samples were infiltrated with three successive changes of 
activated Immuno-Bed (Polysciences) under vacuum at 4°C followed by a final 
embedding step in polyethylene molds. After 48 hours further curing of the blocks at 
room temperature, Immuno-Bed blocks were sectioned at 2 µm thickness. The sections 
were floated on an ultrapure water bath at room temperature and picked up with 
positively-charged glass slides and dried for 24 hours. Sections were deplasticized with a 
solvent exchange routine of xylene, acetone, ethanol, and water before further staining. 
Routine hematoxylene and eosin, trichrome, and immunostaining procedures were 
performed on the deplasticized sections. 
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Microfil perfusion and MicroCT Imaging 
After sacrifice by CO2 inhalation, rats were perfused with 0.9% saline + 4 mg/mL 
papaverine hydrocholoride (Sigma), followed by 0.9% saline, and 10% neutral buffered 
formalin. After fixation, 30 mL of 80% (v/v) diluted MV-122 Microfil (Flowtec) was 
injected into the aorta with a syringe and allowed to polymerize overnight before implant 
retrieval. Explants were scanned at 16 µm resolution with a Scanco μCT-40 microCT 
machine. Contour lines were drawn by hand to define the volume extent of the tissue 
sample and 3D renderings and analysis were performed based on the bone trabecular 





TRANSPLANTATION OF HYDROGEL-ENCAPSULATED 
PANCREATIC ISLETS IN A RAT MODEL OF TYPE-1 DIABETES 
 
Summary 
 Polyethylene glycol maleimide (PEG-4MAL) hydrogel matrices incorporating 
sites for cell adhesion and vascular endothelial growth factor (VEGF) have been 
previously shown to induce an angiogenic response and support pancreatic islet 
engraftment and re-vascularization in healthy rats. We investigated the same 
transplantation model to alleviate hyperglycemia and weight loss in an STZ model of 
diabetes. In three independent trials transplants of 1500 islets failed to reverse 
hyperglycemia although moderate differences were observed in weight gain, fasting 
blood glucose levels, and response to a glucose challenge test. From this information we 
conclude that the animal model represented too severe of a case for the mass of islets 
transplanted to significantly alter the course of the disease state and that impaired 




 After the establishment of the Edmonton Protocol [286], successful 
transplantation of pancreatic islets in humans is performed at select clinics around the 
world with an estimated 750 patients having undergone intraportal islet-alone 
transplantation in the past 10 years [287]. The improvements in islet transplantation 
therapy following the Edmonton Protocol are largely related to transplantation of freshly 
isolated islets from multiple donors and administration of a glucocorticoid-free 
immunosuppressive regimen. Islet transplantation therapy has as its primary objective, 
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elimination of severe episodes of hypoglycemia which is recurrent in approximately 15% 
of patients with type 1 diabetes [287]. Islet transplantation has the secondary benefit of 
freedom from exogenous insulin injections which is an extremely attractive quality of life 
benefit to patients. While still in its infancy as a therapeutic option, and only a handful of 
centers possessing the skill and equipment to carry out the procedure, islet transplantation 
offers a much less invasive alternative to whole pancreas transplantation with similar 
clinical outcomes. It is estimated that 60% to 80% of transplanted islet mass is lost in the 
first hours to days following intra-portal vein infusion due to instant-blood mediated 
inflammatory reaction, ischemia, apoptosis, and a myriad of other factors. Because of the 
high numbers of islets that are lost in the procedure, as many as 5,000 islet equivalents 
(IEQ) or more per kg of body weight are required in human patients, which can require 
two to four donor pancreases depending on the quality of the isolations. A major 
challenge in the development of islet transplantation therapy is to improve the survival 
rate of the transplanted cells. Researchers are working on this problem from all angles 
including improvements to the isolation process, drugs to improve graft acceptance, 
protective materials to encapsulate the islets, and strategies to improve islet engraftment, 
and vascularization. 
 Several animal models of Type 1 diabetes are used in islet transplantation 
research [288]. Non-surgical methods of inducing hyperglycemia include administration 
of the toxins streptozotocin (STZ) and alloxan. Streptozotocin toxin is derived from the 
soil microbe Streptomyces achromogenes. It is a powerful alkylating agent that causes 
double-stranded damage to DNA. Structurally, streptozotocin is similar enough to 
glucose to be transported into cells by the glucose transport protein GLUT2, but is not 
recognized by other glucose transporters. Streptozotocin is preferentially uptaken by 
pancreatic beta cells which have relatively high levels of GLUT2 compared to other cells. 
GLUT2 is also found in the cellular membranes of liver cells, and the brush border 
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membrane of the small intestine. Diabetes can be induced in rodents with a single large 
dose or multiple low doses of streptozotocin.  
 For this study STZ-induced Lewis rats were chosen as the animal model. Rats 
were preferable over mice for their larger size to aid in islet isolation procedures. The 
Lewis rat was chosen as a syngenic inbred stain as both an islet donor and recipient to 
minimize complications from immune rejection of transplanted tissue. In STZ-induced 
rodent models of diabetes, islets have been transplanted with or without immuno-
protective capsules subcutaneously, into the epididymal fat pad, under the renal capsule 
[289], intra-peritoneally, intra-muscularly [290],  into the omentum [137], and  infused 
via the portal vein into the liver. The number of islets in transplantation models which 
successfully reverses diabetic hyperglycemia in ranges from 500 to 4000 islets [291]. 
 Because one of the most significant detrimental factors to islet grafting and 
function is poor vascular perfusion we hypothesized that we could improve the 
physiological outcomes in a diabetic animal model by promoting vascularization of 
transplanted islets. We hypothesized that we would see significant physiological 
improvements in islets transplanted via engineered vascular-inductive PEG-4MAL 
matrices over islets transplanted via the more traditional hepatic portal vein in 
measurements of hyperglycemia, weight gain, circulating insulin levels, c-peptide, and 
response to glucose challenge. This hypothesis is based in the idea that islets transplanted 
in a provascular matrix would avoid islet loss due to instant-blood mediated 
inflammatory reaction and have improve survival and function through increased 
vascularization. We have previously shown that these PEG-4MAL matrices incorporating 
peptides for cell adhesion and the growth factor VEGF are functional delivery vehicles to 




  Male Lewis rats weighing between 200-250 g were made diabetic by a single 
intravenous injection of STZ in citrate buffer (120 mg/kg). Daily monitoring of blood 
glucose levels by tail tip bleeding indicated an immediate jump in blood glucose levels to 
approximately 400 mg / dL within 24 hours of STZ injection for all test subjects. Twenty-
four hours after STZ injection, test subjects began a supplemental insulin regime. 
Diabetic animals received daily injections of 2-4U subcutaneous human glargine 
(Lantus), a long-acting human insulin analog. The expected lifetime of the glargine 
insulin in vivo is ~18 hours, therefore glargine was administered daily immediately 
following the blood glucose check to minimize interference with daily readings. One 
week after STZ injection, rats underwent surgery to receive islet transplants. Islets were 
freshly isolated from healthy male Lewis rats using the methods described previously. 
Islets were isolated 24 hours prior to transplantation and cultured overnight in RPMI 
1640 media supplemented with 10% FBS and 1% Penicillin-Streptomycin. 
 For islet transplants, diabetic subjects received 1500 islets (approximately 2 donor 
pancreases) as either an infusion to the hepatic portal system or in a 4% PEG-4MAL 
hydrogel + 2 mM RGD and 10 µg/mL VEGF165 cross-linked with VPM peptide to the 
small bowel mesentery. Hydrogels were delivered as precursor solutions and cross-linked 
directly onto the tissue so that no suturing was required and a direct hydrogel to tissue 
bond was formed. Islets were delivered dispersed in the bulk of the hydrogel during 
cross-lining. Animals were followed daily for 4 weeks after the transplants for weight 
gain and blood glucose level and compared to control animals which underwent a sham 
surgery but received no islets. 
Three independent trials were conducted to examine the effects of islet 
transplantation augmented by PEG-4MAL matrix delivery in diabetic subjects. In Trial 1 
supplemental glargine dosing was continued throughout the 4 week post-transplant 
period. Animals receiving islets delivered in gels had lower blood glucose levels on 
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average compared to hepatic and sham. However reduction in blood sugar was only 
moderate not enough to reverse hyperglycemia. Animals receiving islets in hydrogel also 
gained weight at a greater rate than the sham or hepatic although they were receiving 
supplemental insulin. Notably these two trends of lower blood sugar and increased 
weight gain only emerged in the time period following islet transplantation indicating 
some positive effect of the islets delivered in hydrogel. 
In Trial 2 supplemental glargine dosing was discontinued 3 weeks after the 
transplant and animals were followed for 1 week without supplemental insulin at the end 
of the trial.  In the time period following islet transplant, both hepatic and hydrogel 
delivered groups had lower blood sugar than sham but were still hyperglycemic although 
hepatic delivery performed better than hydrogel.  Notably animals receiving islets with 
hydrogel delivery dropped below 200 mg / dL for 2 days in the first week following 
transplantation but jumped back up into high range quickly thereafter. Coinciding with 
the moderately reduced blood sugar, the hepatically delivered islet group gained weight 
more rapidly than either gel delivered or sham. After insulin withdrawal during the last 
week, the blood glucose of sham animals skyrocketed to 600 mg / dL and several sham 
animals became immediately ketotic and had to be euthanized.  In the week after insulin 
withdrawal weight gain continued in the hepatic group without supplemental insulin but 
at a lower rate while it plateaued in the gel group. There was not a significantly different 
trend  in blood glucose levels for gel or hepatic groups between before and after 
withdrawal of insulin treatment. 
In Trial 3 supplemental insulin dosing was discontinued at 1 week after the 
transplant and animals were followed for 3 weeks without supplemental insulin. Insulin 
was only given during the first week to help the animals recover from the surgery. Sham 
animals continued to receive supplemental insulin (2 U / day) so that they would not have 
to be euthanized as our previous experience predicted that they would die within 24 to 48 
hours. Healthy animals were also included as a reference for blood glucose levels but did 
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not undergo surgery. After insulin withdrawal, blood glucose increased approximately 
100 mg / dL across the board for all 3 groups. Weight gain was relatively stagnant for all 
3 groups after insulin withdrawal while it had been rising moderately in the week before. 
While animals receiving islets in hydrogel maintained a higher body weight average than 
the other groups of the course of the study, the difference in weight gain only occurred 
during the first week with insulin supplementation and then plateaued. 
At the end of trial 3, animals underwent a glucose tolerance test. Test animals 
were fasted 8 hours overnight prior to the test at which point the received a body weight-
standardized bolus dose of 50% glucose solution by IP injection. Subsequent blood sugar 
monitoring revealed minor differences in glucose response between groups with the sham 
animals’ blood sugar peaking almost 100 mg / dL higher than the gel group. 
 When the transplant sites were examined for islet survival and vascularization it 
was readily apparent that there was very little response to the transplant compared to 
experiments in healthy animals and there were no signs of islets surviving at the implant 
site macroscopically or histologically in any of the trials. Serum samples were collected 
at 4 weeks post-transplant in trial 3 and analyzed for circulating levels of insulin and c-
peptide by ELISA. Animals receiving islets in gels or hepatically did not have detectable 
plasma insulin levels. Sham animals had circulating insulin due to supplemental dosing. 
All diabetic groups had c-peptide below the lowest standard in the kit indicating they 
were producing minimal or no insulin natively. 
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Figure 6.1 Daily blood glucose measurements for diabetic rats in three trials. 
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Figure 6.2 Daily weight measurements for diabetic rats in three trials 
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Figure 6.4 Physiological measurements for diabetic rats at the endpoint of trial 3. (A) 
Blood glucose after 8 hour fasting period. (B) Average of random daily blood glucose 
over 3 week period without supplemental insulin. (C) Plasma insulin levels 4 weeks after 
islet transplantation procedure. (D) C-peptide levels 4 weeks after islet transplantation 











Taken together the data indicate that the islet grafts failed to function as expected 
in the diabetic model with either hepatic portal delivery or gel delivery. The best response 
was observed in the hepatic delivery group in trial 2 where moderate weight gain was 
correlated with a lower but still hyperglycemic blood glucose level. Overall, the lack of 
significant improvements in either weight gain or hyperglycemia in 3 separate trials, no 
detectable circulating insulin or c-peptide, and no signs of surviving islets at the 
transplant site points to the conclusion that the islets failed to graft. 
Macroscopically it was evident that the vascularization response to the matrices 
was diminished in diabetic animals compared to the healthy grafts. Complications from 
diabetic pathology could have resulted in poorer than expected vascularization and 
grafting response in the diabetic animals. Elevated glucose levels have been shown to 
inhibit angiogenesis and vascular density in pancreatic islets [279, 292]. In in vitro 
studies angiogenesis assays of HUVECS in the presence of high glucose revealed 
resulted in a decrease in tubulogenesis [292]. It is not unlikely that the extremely high 
blood glucose levels in the animals impaired vascularization response to the VEGF in the 
gel. 
It is interesting that the animals had no detectable response to the islet graft during 
the first 24-48 hours after the transplant for either hepatic or gel delivery and is an 
indication that the animal model may be too severe for the islet mass delivered. A review 
of the islet transplantation literature indicates that the most commonly administered dose 
of STZ in rats ranges from 50-65 mg / kg [293]while we administered 120 mg / kg. High 
doses of STZ have additional non-specific cyto-toxicity on secondary organs such as the 
liver, kidneys, and intestine. STZ doses of 75, 150, and 200 mg /kg in mice [294] and 60 
mg/kg in rats [295] have been shown to cause liver toxicity, acute kidney damage, and 
development of hyperglycemic nephropathy superimposed on STZ-related renal 
cytotoxicity which can significantly complicate interpretation of results. STZ doses of 
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100 and 150 mg / kg have been associated with high mortality, reduced glycogen 
processing, and reduced responsiveness to insulin therapy[296]. Moderately induced STZ 
diabetic animals should be able to survive for several weeks without supplemental insulin 
dosing while the sham animals in our experiments died within 24-48 hours of insulin 
withdrawal. While less toxic to secondary systems, a single lower dose of STZ may not 
result in full-blown diabetes with total elimination of beta cells. A multiple low-dose 
administration regime is often employed, especially in mice which are more resistant to 
STZ, but this method results in higher variance between test subjects. It is likely that 
were this study to be repeated with a lower STZ dose, the diabetic state would be less 
severe but potentially greater benefits from the islet transplants could be observed. 
Lastly, a third possibility is that the total mass of islets delivered was insufficient 
to generate a detectable response in the animals. Because the animals that did receive 
islets were able to survive without supplemental insulin better than the sham animals, it is 
an indication that there was some benefit from the islet transplant. Since the islets were 
not found at the transplant site, it is possible that the transplanted islets were dislodged 
from the mesentery and grafted elsewhere in the IP cavity, although the survival rate 
must have been extremely low to not generate detectable levels of serum insulin. Our 
estimated delivery of 1500 islets per animal is in agreement with previous reports of 
successful reversal of STZ-induced diabetes [291, 297]. It is unlikely that the gel-
encapsulation process itself is the primary mode of failure as islets were previously 
observed to be viable up to at least one week post-encapsulation, and surviving islets 
using the same gel formulation were successfully grafted in healthy animals. Additionally 






 From the outcomes of these studies we concluded that the diabetic state induced 
in the animals was overly severe for the number of islets being transplanted. Additionally 
we conclude that the success rate of islet grafting was too low to have a significant 
impact. We postulate that future iterations of this experiment should incorporate the 
following changes: Induce a more moderate but still fully hyperglycemic diabetic disease 
state with a lower dose of STZ. Deliver a larger and more concentrated mass of 6,000 
islets instead of 1,500. Incorporate further refinements in the gel design such as an 
immuno-protective coating for islets and incorporate different or additional cytokines 
such as FGF, HGF, and glucagon-like peptide-1 to improve survival rates and 
vascularization. 
 
Materials and Methods 
Induction of diabetes in rats with streptozotocin 
Streptozotocin was solubilized at 88.89 mg / mL in citrate buffer (20 mg / mL 
citric acid, 30 mg / mL sodium citrate, 55 mg / mL D-glucose, pH 4.5) by vortexing at 
37°C for 60 sec, sterile filtered, and then immediately placed on ice. Under general 
anesthesia rats were injected with 120 mg / kg of STZ in citrate buffer through the penile 
vein using an insulin syringe. 
 
Management of STZ-induced diabetes 
The overall diabetic state was monitored daily by body weight, blood glucose, and 
urine ketone level. Daily blood glucose checks were taken by pricking the tail tip with a 
30G ½ inch beveled needle and milking a single blood drop onto a handheld glucose 
meter test strip (Accu-Chek Aviva). In studies 1 and 2, animals were given a daily dose 
of Glargine Insulin (Lantus) according to their daily blood glucose in mg/dL between 2-5 
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U. In Study 3 all animals received the same insulin injection dosing of 2 U Glargine per 
day until 7 days post-transplant at which point insulin was withdrawn from all animals 
receiving islets. Diabetic animals received fresh water and cage changes daily to account 
for excessive urination. Animals were euthanized if they lost more than 20% of their 
initial body weight and did not recover, became severely ketotic, or appeared to be in 
pain or distress and did not respond to insulin or rehydration therapy. 
 
Serum insulin and c-peptide ELISA 
300 uL of blood was collected in heparinized microhematocrit tubes by tail tip 
bleeding. Plasma was separated by microhematocrit centrifugation, extracted from the 
capillary tube, and stored at -80°C. Serum insulin and c-peptide were measured with 
ultra-sensitive rat insulin and c-peptide ELISA kits (Mercodia). 
Glucose tolerance test 
Rats were fasted for 8 hours prior to the test. 2 grams / kg of 50% D-glucose in 
PBS diluted to a standard volume of 2 mL was delivered via IP injection in animals that 
are gently restrained in the head down position with their head covered by a towel to 
minimize stress. At specified time intervals, glucose levels were determined by tail prick 




SUMMARY OF CONCLUSIONS 
 
 The objective of this dissertation was to develop an engineered synthetic matrix 
material that would function to enhance islet transplantation through induced 
vascularization. This objective was proposed to be accomplished through three specific 
aims. 1: Engineering of bio-functionalized hydrogels to support pancreatic islet 
encapsulation. 2: Evaluate the in vivo vascularization potential of the engineered 
hydrogel and islet grafting in healthy rats. 3: Evaluate transplantation of hydrogel-
encapsulated pancreatic islets in a rat model of type-1 diabetes. 
 The initial approach to engineer the hydrogel matrix was based on the photo-
cross-linked PEG-DA platform. PEG-DA achieved the primary design criteria for 
modularity including enzyme-cleavable cross-links, cell adhesion site, and growth factor 
delivery. PEG-DA includes the additional benefit of photo-patterning capability which 
we envisioned could eventually be useful to guide angiogenic morphogenesis into 
specific vascular tree patterns. While we achieved initial success in inducing 
angiogenesis in vivo with PEG-DA hydrogels, the platform ultimately proved 
incompatible for islet encapsulation and transplantation due to poor islet viability in the 
encapsulation process and poor tissue / vascular infiltration into the bulk of the material 
at the small bowel mesentery implant site. These failure modes were attributed to islet 
sensitivity to the UV light and free radical cross-linking process and the high bulk 
polymer density and low swelling ratio of the PEG-DA matrix. We found PEG-DA to be 
extremely unwieldy for in situ delivery due to the low viscosity of the precursor solution 
and UV light requirement for cross-linking. 
 We sought to address these issues by designing a PEG-based hydrogel with 
milder cross-linking chemistry, faster degradation kinetics, and a less dense bulk polymer 
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matrix. We decided to investigate PEG-4MAL as a hydrogel platform due to the 
commercial availability of the macromer and favorable reaction kinetics of the maleimide 
to thiol cross-linking reaction. As there were no previous reports of PEG-4MAL hydrogel 
in the tissue engineering literature, we conducted studies to compare the characteristics of 
PEG-4MAL to similar molecules including PEG-4A and PEG-4VS which have been 
widely employed. Our results were very promising, indicating the PEG-4MAL performed 
better than the established Michael addition hydrogel chemistries in many of our criteria, 
including lower-modulus matrices, cell viability, reaction efficiency, and in situ 
deliverability. 
 PEG-4MAL hydrogels proved to be effective matrices for encapsulation of 
isolated pancreatic islets, preserving viability, insulin expression, and with the addition of 
VEGF, encouraging endothelial sprouting from intra-islet endothelial cells.  Islets 
delivered in PEG-4MAL were successfully grafted in the small bowel mesentery of 
healthy animals and were stably connected to the host vascular system by 4 weeks. 
 We have begun investigate the performance of islets delivered in PEG-4MAL in 
an STZ animal model of Type 1 diabetes. Unfortunately our first several attempts failed 
to show significantly favorable improvements in several physiological indicators, 
ultimately leading to the conclusion that too few islets were surviving the engraftment 
process in the diabetic animals. This result has lead us to refine our delivery strategy to 
account for more immuno-protection for the islets with a dual-layered approach for future 








The PEG-4MAL platform developed as the bio-artificial matrix component of this 
dissertation is a significant leap forward in engineered matrix technology. The 
introduction of maleimide end groups significantly improves reactive efficiency and 
decreases cross-linking time by an order of magnitude. Because the improved maleimide-
based cross-linking results in predictable ligand tethering at near 1:1 stoichiometric 
ratios, the PEG-4MAL platform more successfully fulfills the engineering design 
requirement for controlled and predictable incorporation of bioactive signals than the 
alternative chemistries PEG-4VS and PEG-4A. Cross-linking speeds on the order of one 
minute solves a significant in situ delivery problem where the gel must set up quickly to 
maintain shape and position. Importantly the maleimide group’s high-affinity to form 
covalent bonds with thiols allows the PEG-4MAL gel to bond itself to thiols present in 
tissue, opening up a huge repertoire of potential future directions. 
 
Islet transplantation model 
 While the islet transplantation efforts on this project to date have not rescued 
diabetic rats from STZ-induced hyperglycemia, the design flexibility of the material 
allows for future modifications to improve transplant acceptance and test new ideas. In a 
new design variation, dual-layer engineered polyethylene glycol maleimide (PEG-
4MAL) hydrogels are designed to shield transplanted cells from the host immune system 
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and enhance engraftment and vascularization of the shielded islets with a vascular-
inductive PEG-4MAL matrix as the transplantation vehicle (Fig. 8.1).  We hypothesize 
that micro-bead encapsulated islets transplanted within vascular-inductive bulk PEG-
4MAL matrices will lead to improved vascularization in the vicinity of the micro-
capsules which in turn will hinder immune rejection responses to the islets themselves. 
 
Fig. 8.1: Schematic of dual-layered hydrogels for islet engraftment and function 
 
This approach is entirely different from other encapsulation vehicles that attempt 
to achieve immuno-isolation alone and serve as simple delivery vehicles (e.g., alginate). 
Furthermore, we expect that immunoprotection can be achieved in outbred animals 
without immune suppression or co-stimulatory blockade while simultaneously enhancing 
islet survival and vascularization. Micro-encapsulation of islets will be achieved by 
flowing a precursor solution of islets and PEG-4MAL through an air jet encapsulation 
needle where droplets fall into a bath of dilute di-thiol non-degradable cross-linker. By 
varying reaction conditions, the thickness and structure of the hydrogel coating can be 
controlled. Because PEG-4MAL hydrogels are nano-porous, they provide an effective 
barrier to host immune cells but allow for transport of nutrients/waste and insulin. We 
hypothesize that these materials will support encapsulated islet survival and endocrine 
function in vitro as measured by viability assays, insulin/glucagon production, and 
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glucose challenge responsiveness. In addition we will assess the effects of tethering 
glucagon-like peptide-1 to the PEG-4MAL micro-capsules, a factor known to enhance 
the function of PEG-encapsulated islets [268]. 
 
Tissue Engineering 
 Outside of islet transplantation, PEG-4MAL shows promise in a variety of tissue 
engineering models. Our lab is developing materials-based applications in bone repair 
and regeneration where PEG-4MAL matrices incorporate the adhesive ligands GFOGER 
[298] and FNIII7-10 [299] to target osteo-specific integrin receptors and subsequently 
initiate bone repair signaling [300, 301]. Tubular scaffolds are designed to bridge non-
healing long-bone fractures and are filled with osteo-inductive hydrogel. 
We are also developing models employing PEG-4MAL hydrogel for post-
myocardial infarction repair and regeneration. We are experimenting with synergistically 
delivering growth factors VEGF and HGF bound to PEG-4MAL matrices cross-linked 
intra-myocardially. Preliminary data shows improved vascularization in the infarct area 
and improved left ventricular ejection fraction after treatment. In a similar study of infarct 
regeneration, we are using PEG-4MAL matrices to deliver alginate-encapsulated bone-
marrow stromal cells to the surface of infarcted myocardium. The encapsulated stromal 
cells, which produce regenerative growth factors and cytokines, have much higher 
viability and are retained at the injury site longer when delivered using PEG-4MAL than 
alginate-encapsulated cells or cells delivered alone. Lastly we are in the beginning stages 
of using PEG-4MAL delivery of RNAi to repair aortic aneurisms and delivery of cells 
and growth factors to treat chronic limb ischemia. All of these models were developed 




 PEG-4MAL hydrogel is very useful for basic scientific studies. The intrinsically 
non-adhesive background of the bulk PEG material provides an environment where the 
interactions between cells and ligands at specific densities can be studied in three 
dimensions. Material degradation and elastic modulus can be independently altered and 
examined. We are currently investigating the use of PEG-4MAL matrices to direct stem 
cell differentiation through the controlled presentation of integrin-specific ligands. We 
are also employing PEG-4MAL hydrogels as synthetic microenvironments for epithelial 
morphogenesis. Epithelial cells encapsulated in PEG-4MAL, under the right matrix 
formulations, recapitulate the cyst-structure formation seen in natural matrices [131]. 
Incorporation of bioactive motifs such as degradable cross-linking sequences and cell-
adhesion ligands, as well as hydrogel material density (polymer weight / volume 
percentage) have significant impact on cyst formation. 
 
Smart Materials 
Finally, we are investigating PEG-4MAL matrices for the fabrication of dynamic 
materials. In one project, we are working to develop a contractile cellular machine 
combining skeletal myocytes with nerve cell networks, using PEG-4MAL hydrogel as a 
highly-defined and engineered extracellular matrix material. We are also investigating the 
use of PEG-4MAL in materials with dynamic cell-adhesion ligands. We are working with 
an RGD peptide with a photo-labile masking group [302] to dynamically present 
adhesive ligands with the ability to turn adhesion on and off with temporal and special 
control to modulate such factors as inflammatory response and cell-differentiation timing. 
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